Moving towards effective drug delivery technologies and deal making
1st - 2nd February 2011, BSG Conference Centre, London, UK
Key Speakers:
Dr. Sven Stegemann, Director, Pfizer
Dr. Sophie Van Tomme, Pharmaceutical Scientist, Abbott
Gerrit Hauck, Head PSD R&D Operations, Sanofi -Aventis
Matthew Roe, Senior Director-Business Development and Licensing, Genzyme
Dr. Oliver Steinbach, Department Head, Philips Research Laboratories
Dr. Rajan K. Verma, Senior Manager Early Development Formulations – Generics Integrated Product Development (IPDO), Dr Reddy’s Laboratories
Dr. Deirdre McIntosh, Director, McIntosh Scientific Advice Services
Dr. Michel Deleers, CEO, OncoBel
Dr. Andrew Lewis, Operations Director, Critical Pharmaceuticals
Dr. Ben Forbes, Senior Lecturer in Pharmaceutics, King’s College, London
Ketan Pancholi, Lecturer, The Robert Gordon University
Gerry Kamstra Partner, IP & Life Sciences, Bird and Bird
Conference Introduction
Shrinking global capital markets, new healthcare policies, ageing populations, the growth of emerging economies, technological advances and the advent of regenerative and biological medicines are just some of the factors expected to shape the future drug delivery device market. (Source: Cambridge Consultants UK, September 2009)
With increased competition and the growing importance of patience compliance, pharmaceutical companies are working towards developing effective and targeted drug
delivery systems, to transform disease treatments. Now in its 6th year, Drug Delivery Systems Conference showcases the basics and latest developments for inhaled drug, RNAi based therapies and protein and peptide methods. We have put together an unparalleled scientific programme comprising insightful presentations by leading experts from Pfizer, Philips Research, Dr Reddy’s Laboratories and Genzyme. This conference will feature keynote addresses, case studies and interactive discussions
ranging from current and evolving drug delivery technologies to advancement and manufacturing of more efficient formulations.
Attendance at this conference will enable you to:
*
Benefit from thorough updates of recent developments in the drug delivery sector
*
Examine challenges in generic development of drug delivery systems
*
Learn from in-depth case study from Philips about image-guided ultrasound-mediated drug delivery
*
Identify different strategies in managing a drug delivery alliance
*
Know how to overcome the industry challenges for inhaled delivery systems
*
Discuss key regulatory and legal issues
*
Recognise the importance of new biologic delivery technologies
*
Discuss microbubble production technologies and its effect on delivery
*
Create patient centered drug delivery product
*
Network with experts and opinion leaders from pharma, biotech, device and drug delivery industries
Who should attend?
VPs, Directors, Heads, Managers of:
*
Drug Delivery
*
Preformulation /Formulation/Stability
*
Business Development
*
Licensing
*
Technology Assessment
*
Commercial Development
*
Patents
*
Lifecycle Management
*
Strategic Planning and Development
*
Financial Analyst
*
Pharmaceutical and Analytical R&D
*
Pharmaceutical Science
*
Testing
*
Product Development
*
New Product Planning]
*
New Technology Evaluation
*
Marketing
*
Brand Management
*
Product Management
*
Sales
*
Regulatory Affairs
Others:
*
Intellectual Property Attorneys
*
Venture Capitalists
*
Medical Device Companies
*
Analysts/Investment Banks
CROs:
*
Contract Sales Organisations
*
Universities and Government Research
*
Testing and Manufacturing Equipment
*
Packaging Companies
Day 1
6th Annual Drug Delivery Systems
Tuesday 1st February 2011
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Imagine a patient would run a formulation lab: Patient centered drug delivery product development
*
From clinical perspectives to therapeutic objectives
*
Identifying patient needs beyond the clinical symptoms
*
Translating scientific excellence in real world therapy enhancement
*
Integrating patient centered drug delivery in healthcare provision
Dr Sven Stegemann
Director, Pfizer
10:20 Realising partnerships with academia, SME’s and Big E in the field of inhalation.
*
The NeoFor project (New formulation and Devices for the inhalation of Macromolecules)
*
Anticancer drug project for lung cancer (Solid lipidic micro particles formulations)
*
Formulations for 2 and 3 molecules
*
Formulations with pegylated mAb’s
*
Other projects in partnering
Dr. Michel Deleers
CEO, OncoBel. Former VP New Pharma Technologies & Academic Liaison, UCB New Medicines
11:00 Morning refreshments
11:20 Inhalation delivery systems: the challenges and opportunities
*
Retention in the lung
*
Absorption from the lung
*
Safety and efficacy
*
Industry challenges & open innovation
Dr. Ben Forbes
Senior Lecturer in Pharmaceutics, King’s College, London
12:00 Sponsor Spotlight Session
Take this unique opportunity to be a part of the conference theme, network, share ideas and provide an overview of your product/services to the audience.
12:40 Networking lunch
13:40 Virtual training course for development of nanoparticulate dosage forms From API to final nanoparticulate drug products
*
Pros and cons of various particle size reduction technologies
*
Practical development tools (Stabilizer screening, Particle size measurements, Solid state analysis, Final dosage form manufacturing, Dissolution aspects, Stability studies)
*
Biopharmaceutical aspects
Dr. Sophie Van Tomme
Pharmaceutical Scientist, Abbott
14:20 Targeted drug delivery using microbubble - An overview
*
Possible approaches of delivering drug using microbubble
*
Microbubble production technologies and its effect on delivery
*
Drug delivery mechanism
*
Advantages and challenges
*
Summary
Ketan Pancholi
Lecturer, The Robert Gordon University
15:00 Afternoon Refreshments
15:20 IMAG(IN)E global-release local - IMAGE guided ultra sound-triggered drug delivery for RNAi-based therapy
*
Medical imaging technologies are becoming an integral part of therapeutic interventions. The development of ultrasound techniques that could non-invasively trigger the delivery of new drug formats such as RNAi therapeutics at a targeted location opens up exciting possibilities for advancing personalized medicine. A key success factor for the effective translation of new drug delivery concepts into clinical practice are partnerships with leading academic, medical institutions and industrial partners.
*
Philips’ image-guided ultrasound-mediated drug delivery platform offers researchers a unique approach to investigating the delivery of various therapeutic molecules and capitalizes upon Philips’ existing expertise in medical imaging technologies for diagnosis, therapy planning and minimally-invasive medical procedures. We show advances in temperature sensitive liposomes with incorporated drugs and MRI-imaging labels as well as pressure-sensitive microbubbles with specific ultrasound-imaging and drug release characteristics for the local delivery of nucleic-acid based therapeutics including siRNA.
Dr. Oliver Steinbach
Department Head, Philips Research Laboratories
16:00 Ocular Drug Delivery Systems
*
Challenges and advantages of conventional dosage forms
*
Analysing recent trends in ocular inserts
*
Closing remarks from the chair
16:50 Networking drinks
Day 2
6th Annual Drug Delivery Systems
Wednesday 2nd February 2011
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Targeted drug delivery strategies in cancer therapy: The evolution of early concepts
*
Naive concepts in early targeting
*
Toxins as chemotherapeutic agents,
*
Liposomes as Toxin Vectors
*
Physiological barriers to success
*
The emergence of holistic strategies.
Dr. Deirdre McIntosh
Director, McIntosh Scientific Advice Services
10:20 Protein and peptide drug delivery strategies for product lifecycle management
*
Why is new biologic delivery technologies needed?
*
Innovative technologies to deliver therapeutic macromolecules:
- CriticalMix – injectable sustained release of macromolecules
- CriticalSorb – systemic delivery of macromolecules via the intranasal route
Dr. Andrew Lewis
Operations Director, Critical Pharmaceuticals
11:00 Morning refreshments
11:20 Drug synthesis and delivery IP due diligence
*
Importance of IP protecting manufacturing process and drug delivery technology in late stage investments
*
Typical issues around manufacturing process patents
*
Typical issues around drug delivery patents
*
Subsistence of Supplementary Protection Certificates
*
Regulatory data protection and orphan drug
*
Protection in late stage investments
Gerry Kamstra
Partner, IP & Life Sciences, Bird and Bird
12:00 Parenteral sustained release drug delivery systems - Status and perspective
Gerrit Hauck
Head PSD R&D Operations, Sanofi-Aventis
12:40 Networking lunch
13:40 Innovations in generic development of drug delivery systems
*
Drug delivery systems
*
Challenges in generic development of drug delivery systems
- Regulatory
- IP
- Bio requirements
- Technological
*
Case studies
Dr. Rajan K. Verma
Senior Manager Early Development Formulations – Generics Integrated Product Development (IPDO)
Dr Reddy’s Laboratories]
14:20 Different strategies in managing a drug delivery alliance
Matthew Roe
Senior Director-Business Development and Licensing, Genzyme
15:00 Afternoon refreshments
15:20 Sponsor Spotlight Session
Take this unique opportunity to be a part of the conference theme, network, share ideas and provide an overview of your product/services to the audience.
16:00 Drug delivery in diabetes
*
Examining various techniques
*
Discussing emerging insulin delivery methods
*
Understanding pricing and reimbursement
16:40 Chair’s closing remarks
16:50 End of Conference
For more information visit
http://www.bharatbook.com/detail.asp?id=111630&rt=Conference-on-6th-Annual-Drug-Delivery-Systems.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Your one-stop-shop for business information
Showing posts with label Drugs Related. Show all posts
Showing posts with label Drugs Related. Show all posts
Monday, July 26, 2010
Sunday, July 25, 2010
Conference on Phase I Clinical Trials Summit
Conference on Phase I Clinical Trials Summit
Strategies for improving Phase I trial design, management and execution
To be held at 28th – 29th October 2010, BSG Conference Centre, London, UK
Key Speakers
Dr. Eckhard von Keutz, Senior Vice President Head Global Early Development, Bayer Schering Pharma
Dr. Walter Janssens Coordinator Early Phase Development, FAGG/AFMPS
Corina Dota ECG Centre Manager, Medical Science Sweden, AstraZeneca
Dr. Fatiha Sadallah, Principal Scientifi c Manager, Innovative Medicines Initiative (IMI)
Dr. Andrea Laslop, Head of Institute Science and Information, AGES PharmMed
Rob Nichols, Director of Commercial Development, Phase Forward Europe
Dr. Finbarr Cotter Prof of Haematology, Medical Oncology, Barts and the London School of Medicine
Robert Blakie, Director, ERA Consulting
Dr. Assem S. el Baghdady, Director, Alpha Beta Pharma
Dr. Jennifer J. Wheler, Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer
Medicine, The University of Texas M. D. Anderson Cancer Center
Professor Atholl Johnston, Professor of Clinical Pharmacology, Barts and the London School of Medicine and
Dentistry, Queen Mary University of London
Dr. Dominic Williams, MRC Centre for Drug Safety Science, The University of Liverpool
Who should attend?
Vice/Presidents, Directors, Heads of:
• Clinical Operations • Clinical Research
• Clinical Development
• Exploratory Development
• Strategic Drug Development
• Clinical Trial Design
• Clinical Pharmacology / Pharmacometrics
• Quality Assurance / Quality Control • Pharmacokinetics/ Pharmacodynamics
• Project Management
• Regulatory Affairs
• Scientifi c Relations
• Statistical Methodology
Day 1
Phase I Clinical Trials Summit
Thursday 28th October 2010
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 The use of biomarkers early in clinical development
• Biomarkers as go/no-go in early clinical development
• Do biomarkers worth the cost or the time?
• Can we use biomarkers in late clinical development too?
• What role do biomarkers play in the clinic?
Dr. Assem S. el Baghdady
Director, Alpha Beta Pharma
Formerly Medical Director R&D, Norgine
10:20 Exploring translatability from phase I to phase IIb
• Clarify different concepts of biomarkers
• Speed up the transition from Phase I to Phase IIb
• Integrative assessment of available data
• Designing biomarker studies efficiently for informative decision making in clinical development
• Illustrative example in diabetes
Dr. Arne Ring
Team Leader Biostatistics Phase I/IIa
Boehringer Ingelheim Pharma
11:00 Morning refreshments
11:20 Regulatory experience with exploratory clinical trials
• Critical issues in the trial application
- preclinical
- quality issues
- protocol related
• Experience in Belgium with exploratory clinical trials
Dr. Walter Janssens
Coordinator Early Phase Development
FAGG/AFMPS
12:00 Phase I clinical trials: beside to bench
Dr. Jennifer J. Wheler
Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
The University of Texas M. D. Anderson Cancer Center
12:40 Networking lunch
13:40 Reducing the cost of clinical QT studies
• Relationship between the electrocardiographic precision and the study size
• Electrocardiographic methods to increase measurement precision
• Design implications for crossover and parallel studies
• Advantages of continuous ECG acquisition
• Optimum combinations of computerised and manual readings to reduce the cost of ECG analysis
Marek Malik
Professor of Cardiac Electrophysiology, Head, Noninvasive Electrocardiology
St. George’s, University of London
14:20 Evaluating the efficiency of design methods and implementing early clinical trials with novel therapeutics
• Determine dose and schedule
• Discuss continual reassessment methods
• Study specific target patient populations
15:00 Afternoon refreshments
15:20 Study design for Leukaemia therapy
• What does we mean by Phase I studies in the context of Leukaemia
• What are the goals
• How do we design the study
• How to we record and evaluate the trial
• What are added value studies
Dr. Finbarr Cotter
Prof of Haematology, Medical Oncology
Barts and the London School of Medicine
16:00 Update on ICH guidelines
• Review the guidelines
• Discuss the risk benefit
• Examine the regulatory requirements
16:40 Closing remarks from the chair
16:50 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting.
Day 2
Phase I Clinical Trials Summit
Friday 29th October 2010
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Preparing phase I clinical trials
• Early clinical trials methodology
• Principles of laboratory methodologies
• Reviewing preclinical data
Professor Atholl Johnston
Professor of Clinical Pharmacology, Barts and the London
School of Medicine and Dentistry
Queen Mary University of London
10:20 Understanding the importance of preclinical
studies for clinical success
• What has changed?
• What is necessary?
• Opportunities for better investigations
• Opportunities for cross-functional cooperation
Dr. Eckhard von Keutz
Senior Vice President, Head, Global Early Development
Bayer Schering Pharma
11:00 Morning refreshments
11:20 Clinical trials data management in phase I
12:00 The case for automating phase I clinical trials
• Understand the unique challenges for phase I clinical units and how these can be addressed by improved use of automated
solutions
• Appreciate the breadth of available solutions suitable for phase I
• Understand the key issue areas to consider when planning a
smooth implementation
Rob Nichols
Director, Commercial Development
Phase Forward Europe
12:40 Networking lunch
13:40 Translational medicine in Europe: Role of the innovative medicines initiative :IMI
• Public-private partnership in the health sector
• Building on strengths and tackling weaknesses in the EU
• IMI first two calls for proposals
Dr. Fatiha Sadallah
Principal Scientific Manager
Innovative Medicines Initiative (IMI)
14:20 Presentation to be announced
Dr. Andrea Laslop
Head of Institute Science and Information
AGES PharmMed
15:00 Afternoon refreshments
15:20 Cardiovascular risk profiling in early clinical development
• Role of preclinical testing for cardiovascular safety profiling
• What can be achieved in the early phase 1 studies?
• What are the technologies at hand to ensure quality and cost efficiencies in early clinical development
Corina Dota
ECG Centre Manager, Medical Science Sweden
AstraZeneca
16.00 Mechanism-based markers of murine drug-induced liver injury
• Paracetamol as a tool for translational hepatotoxicity
• Use of keratin-18 as a serum marker of apoptosis
• Use of High Mobility Group box-1 as a serum marker of necrosis
• Fed and fasted animal models in pre-clinical development
Dr. Dominic Williams
MRC Centre for Drug Safety Science, Dept.
Pharmacology & Therapeutics
The University of Liverpool
16:40 Chair’s closing remarks
16:50 End of conference
For more information visit
http://www.bharatbook.com/detail.asp?id=136318&rt=Conference-on-Phase-I-Clinical-Trials-Summit.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Strategies for improving Phase I trial design, management and execution
To be held at 28th – 29th October 2010, BSG Conference Centre, London, UK
Key Speakers
Dr. Eckhard von Keutz, Senior Vice President Head Global Early Development, Bayer Schering Pharma
Dr. Walter Janssens Coordinator Early Phase Development, FAGG/AFMPS
Corina Dota ECG Centre Manager, Medical Science Sweden, AstraZeneca
Dr. Fatiha Sadallah, Principal Scientifi c Manager, Innovative Medicines Initiative (IMI)
Dr. Andrea Laslop, Head of Institute Science and Information, AGES PharmMed
Rob Nichols, Director of Commercial Development, Phase Forward Europe
Dr. Finbarr Cotter Prof of Haematology, Medical Oncology, Barts and the London School of Medicine
Robert Blakie, Director, ERA Consulting
Dr. Assem S. el Baghdady, Director, Alpha Beta Pharma
Dr. Jennifer J. Wheler, Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer
Medicine, The University of Texas M. D. Anderson Cancer Center
Professor Atholl Johnston, Professor of Clinical Pharmacology, Barts and the London School of Medicine and
Dentistry, Queen Mary University of London
Dr. Dominic Williams, MRC Centre for Drug Safety Science, The University of Liverpool
Who should attend?
Vice/Presidents, Directors, Heads of:
• Clinical Operations • Clinical Research
• Clinical Development
• Exploratory Development
• Strategic Drug Development
• Clinical Trial Design
• Clinical Pharmacology / Pharmacometrics
• Quality Assurance / Quality Control • Pharmacokinetics/ Pharmacodynamics
• Project Management
• Regulatory Affairs
• Scientifi c Relations
• Statistical Methodology
Day 1
Phase I Clinical Trials Summit
Thursday 28th October 2010
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 The use of biomarkers early in clinical development
• Biomarkers as go/no-go in early clinical development
• Do biomarkers worth the cost or the time?
• Can we use biomarkers in late clinical development too?
• What role do biomarkers play in the clinic?
Dr. Assem S. el Baghdady
Director, Alpha Beta Pharma
Formerly Medical Director R&D, Norgine
10:20 Exploring translatability from phase I to phase IIb
• Clarify different concepts of biomarkers
• Speed up the transition from Phase I to Phase IIb
• Integrative assessment of available data
• Designing biomarker studies efficiently for informative decision making in clinical development
• Illustrative example in diabetes
Dr. Arne Ring
Team Leader Biostatistics Phase I/IIa
Boehringer Ingelheim Pharma
11:00 Morning refreshments
11:20 Regulatory experience with exploratory clinical trials
• Critical issues in the trial application
- preclinical
- quality issues
- protocol related
• Experience in Belgium with exploratory clinical trials
Dr. Walter Janssens
Coordinator Early Phase Development
FAGG/AFMPS
12:00 Phase I clinical trials: beside to bench
Dr. Jennifer J. Wheler
Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
The University of Texas M. D. Anderson Cancer Center
12:40 Networking lunch
13:40 Reducing the cost of clinical QT studies
• Relationship between the electrocardiographic precision and the study size
• Electrocardiographic methods to increase measurement precision
• Design implications for crossover and parallel studies
• Advantages of continuous ECG acquisition
• Optimum combinations of computerised and manual readings to reduce the cost of ECG analysis
Marek Malik
Professor of Cardiac Electrophysiology, Head, Noninvasive Electrocardiology
St. George’s, University of London
14:20 Evaluating the efficiency of design methods and implementing early clinical trials with novel therapeutics
• Determine dose and schedule
• Discuss continual reassessment methods
• Study specific target patient populations
15:00 Afternoon refreshments
15:20 Study design for Leukaemia therapy
• What does we mean by Phase I studies in the context of Leukaemia
• What are the goals
• How do we design the study
• How to we record and evaluate the trial
• What are added value studies
Dr. Finbarr Cotter
Prof of Haematology, Medical Oncology
Barts and the London School of Medicine
16:00 Update on ICH guidelines
• Review the guidelines
• Discuss the risk benefit
• Examine the regulatory requirements
16:40 Closing remarks from the chair
16:50 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting.
Day 2
Phase I Clinical Trials Summit
Friday 29th October 2010
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Preparing phase I clinical trials
• Early clinical trials methodology
• Principles of laboratory methodologies
• Reviewing preclinical data
Professor Atholl Johnston
Professor of Clinical Pharmacology, Barts and the London
School of Medicine and Dentistry
Queen Mary University of London
10:20 Understanding the importance of preclinical
studies for clinical success
• What has changed?
• What is necessary?
• Opportunities for better investigations
• Opportunities for cross-functional cooperation
Dr. Eckhard von Keutz
Senior Vice President, Head, Global Early Development
Bayer Schering Pharma
11:00 Morning refreshments
11:20 Clinical trials data management in phase I
12:00 The case for automating phase I clinical trials
• Understand the unique challenges for phase I clinical units and how these can be addressed by improved use of automated
solutions
• Appreciate the breadth of available solutions suitable for phase I
• Understand the key issue areas to consider when planning a
smooth implementation
Rob Nichols
Director, Commercial Development
Phase Forward Europe
12:40 Networking lunch
13:40 Translational medicine in Europe: Role of the innovative medicines initiative :IMI
• Public-private partnership in the health sector
• Building on strengths and tackling weaknesses in the EU
• IMI first two calls for proposals
Dr. Fatiha Sadallah
Principal Scientific Manager
Innovative Medicines Initiative (IMI)
14:20 Presentation to be announced
Dr. Andrea Laslop
Head of Institute Science and Information
AGES PharmMed
15:00 Afternoon refreshments
15:20 Cardiovascular risk profiling in early clinical development
• Role of preclinical testing for cardiovascular safety profiling
• What can be achieved in the early phase 1 studies?
• What are the technologies at hand to ensure quality and cost efficiencies in early clinical development
Corina Dota
ECG Centre Manager, Medical Science Sweden
AstraZeneca
16.00 Mechanism-based markers of murine drug-induced liver injury
• Paracetamol as a tool for translational hepatotoxicity
• Use of keratin-18 as a serum marker of apoptosis
• Use of High Mobility Group box-1 as a serum marker of necrosis
• Fed and fasted animal models in pre-clinical development
Dr. Dominic Williams
MRC Centre for Drug Safety Science, Dept.
Pharmacology & Therapeutics
The University of Liverpool
16:40 Chair’s closing remarks
16:50 End of conference
For more information visit
http://www.bharatbook.com/detail.asp?id=136318&rt=Conference-on-Phase-I-Clinical-Trials-Summit.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Conference on 7th Annual Pain Management
Conference on 7th Annual Pain Management
Accelerating innovation in drugs and devices for successful pain management
18th – 19th October 2010, BSG House, London, UK
Background Info
Key Speakers
• Theo F. Meert, Senior Research Fellow, Neuroscience, Johnson & Johnson
• Iain Chessell, VP Neuroscience, MedImmune
• Steve England, Associate Research Fellow, Pfizer
• Anne Estrup Olesen, Mech-Sense, Department of Gastroenterology,Aalborg University
• Anastasia Liapi, Director Business Development & New Product Leader CNS & Pain, Astellas
Extensive availability of generic drugs, pipeline products and increasing demand for efficient medical devices has accelerated growth of the global pain management marketplace. However recent issues involving patent expiries of top NSAID’s drugs, regulatory approvals and safety of analgesics classes are posing a huge challenge to this sector. How rapid will the pain management market grow in the next 10 years? What are the evolving segments of pain management and which new drugs in the pipeline will take the leap?
Join us at 7th Annual Pain Management Conference, where our expert panel of speakers, will share insights on ‘first-to-market’ opportunities, pivotal to achieve success in the global pain market across drugs and devices. With a special spotlight on innovations in analgesics, pipeline drugs and clinical breakthrough for chronic pain therapies, the conference will be an unmissable opportunity to maximise your knowledge and network with diverse industry leaders from the pain management sector.
Learn, exchange ideas and acquire knowledge on:
• Maximising the role of opioids in treatment of persistent pain
• Assessing the market dynamics of chronic pain and key pipeline development
• Gaining new insights into migraine pain and the molecular basis of effective therapeutics
• Developing spinal cord stimulation (SCS) for chronic pain of neuropathic
• Evaluating analgesic effect in experimental visceral pain models through translational pain research
• Examining pathophysiology of cancer pain and opioid tolerance
• Understanding the role of voltage-gated sodium channels in neuropathic pain
• Implementing target nerve growth factor (NGF) for pain therapy
• Devising a new methodology to measure quality of recovery from anaesthesia
• Developing a two step approach for treating diabetic neuropathy: eliminating the cause and relieving the symptoms
• Reviewing novel mechanisms for future pain therapies
Who should attend?
Presidents, CEOs, Vice-Presidents, CSOs, Directors, Senior Business Developers, Researchers and Professors in:
• Analgesia
• Pain Therapies/Research
• Neurosciences/ Neuropharmacology/ Neurology
• CNS Clinical Discovery/Nervous System Research
• Arthritis
• Migraine
• Drug Discovery
• Emerging Targets/Lead Optimisation
• Therapeutics and Molecular Profiling
• Pre-Clinical/Clinical R&D
• Genomics/Proteomics/Bioinformatics/Neuroinformatics
• Translational Medicine
• Imaging
• Regulatory Affairs
• Business Development
• Licensing and External Research
• Quality Control/Assurance
• Global Marketing and Medicine
Day 1
7th Annual Pain Management
Monday 18th October 2010
09:30 Registration and refreshments.
10:00 Opening address from the chair.
Chas Bountra
Chief Scientist, Structural Genomics Consortium, University of Oxford
10:10 A world of pain: Current and future market dynamics.
• Market dynamics in key pain indications and emerging trends.
• Changes in industrial landscape during the last year: Who is still standing and new kids on the block?
• Commercial considerations during drug development: R&D with the end in mind.
Anastasia Liapi
Director, Business Development Astellas
10:50 Developing a two step approach for treating diabetic neuropathy: Eliminating the cause and relieving the symptoms.
• Management of symptomatic diabetic sensory neuropathy: A therapeutic challenge.
• Using Aanticonvulsant and antiarrhythmic agents, and opioid-like medications.
• Topical therapies and non pharmalogic approaches.
• Recent advances in the diagnosis and management of diabetic neuropathy.
Dr James Campbell
CEO, Arcion Therapeutics
Professor, Department of Neurosurgery, School of Medicine Johns Hopkins University
11:30 Morning refreshments.
11:50 The use of biologic therapies for pain management: The next revolution?
• Review on how biologic therapies accelerate pain management: An analysis of preliminary data.
• Evaluating mAbs over traditional therapies: Target engagement, on- versus off-target tolerability profiles and potency/affinity.
• Examining the pros and cons of biologic therapies for pain.
• Current and future directions in pain management through biologic therapies.
Iain Chessell
Vice President, Neuroscience MedImmune
12:30 Voltage-gated sodium channels in neuropathic pain.
• What happens to sodium channels following peripheral nerve damage?
• What do the preclinical models tell us?
• If we find the right sodium channel modulator, will it work in the clinic?
• Future perspectives.
Steve England
Associate Research Fellow Pfizer
13:10 Networking lunch.
14:10 Evaluating analgesic effect in experimental visceral pain models through translational pain research.
• Assessing the challenges in pathophysiology of deep visceral pain.
• Optimising treatment and improving knowledge of the mechanisms and mode of action of analgesic substances.
• Experimental human visceral pain research for evaluation of analgesic action.
• Bridging the gap for translational pain research.
Anne Estrup Olesen
Mech-Sense, Department of Gastroenterology Aalborg University
14:50 What is the impact of chromatin modifications on establishing chronic pain state?
• Role of early life experiences.
• Can these changes be modulated to deliver new therapies?
• Will they be superior targets for drug discovery?
• Potential targets.
Chas Bountra
Chief Scientist, Structural Genomics Consortium, University of Oxford
15:30 Afternoon refreshments.
15.50 NSAIDs for Pain management: Safety and efficacy of NSAIDs.
NSAIDs are among the most common pain relievers in the world. And lately, they’re among the most controversial. Through this panel a discussion we will discuss the benefits and risks of NSAIDs.
16:30 Exploiting cannabinoids for pain relief: Current and emerging pharmacological strategies.
• Current strategy for targeting cannabinoid receptors.
• Emerging strategies for targeting cannabinoid receptors.
• Results from clinical trials.
17:10 Closing remarks from the chair.
17:20 Networking drinks.
Take your discussions further and build new relationships in a relaxed and informal setting.
Day 2
7th Annual Pain Management
Tuesday 19th October 2010
09:30 Registration and refreshments.
10:00 Opening address from the Chair.
Dr Dic Williams
Research Fellow, Pain Therapeutics Pfizer
10:10 Development of treatments for peripheral neuropathies.
• Existing treatment options.
• Preclinical research.
• Growth factors.
• POC modeling in humans.
Theo F Meert
Professor, Katholieke Universiteit Leuven and University of Antwerp
Senior Research Fellow, Neuroscience Johnson and Johnson
10:50 Human experimental pain models in early drug development.
• Translation from animal to human pain models.
• Back-translation from human models to animal models.
• Translating from human experimental pain models in volunteers to pain patients.
• Mechanisms based proof-of-concept studies.
• The concept of multi-model, multi-tissue pain models.
• Integrating pain models in phase Ib studies.
Prof Anthony Jones
Professor of Neuro-rheumatology,
Human Pain Research Group University of Manchester
11:30 Morning refreshments.
11:50 Advancements and emerging therapies for neuropathic pain.
• Emerging therapies for neuropathic pain.
• Current challenges: High unmet medical needs for new treatments with better efficacy and improved tolerability.
• Investigation of novel targets.
Jonathan Stewart
Honorary Consultant, Pain Medicine St Mary’s Hospital
12:30 What is the impact of chromatin modifications on establishing chronic pain state?
• Role of early life experiences.
• Can these changes be modulated to deliver new therapies?
• Will they be superior targets for drug discovery?
• Potential targets.
Chas Bountra
Chief Scientist, Structural Genomics Consortium University of Oxford
13:10 Networking lunch.
14:10 Cannabinoids and opioids: Case for synergy.
• Pharmacologic basis for a positive interaction.
• Animal studies.
• Clinical study concept validation.
Stephen Wright
Research and Development Director GW Pharmaceuticals
Prof Roger Pertwee
Professor of Neuropharmacology University of Aberdeen
14:50 Development of novel NSAIDs and COX-2 inhibitors in the post-Vioxx era.
• What have we learned about GI and cardiovascular risk?
• What strategies are being employed to improve GI and cardiovascular safety?
- Example #1: Naproxcinod, a nitric-oxide donating analog of naproxen.
- Example #2: CG100649, a dual inhibitor of COX-2 and carbonic anhydrase.
• Are regulatory hurdles manageable in the USA and Europe?
15:30 Afternoon refreshments.
15.50 Future pain management: emerging new mechanisms and modalities.
• Overview of the established pain relief mechanisms: Non-steroidal anti-inflammatory and opiates.
• Maximising therapeutic benefit and efficacy of pain relief mechanisms.
- Development of innovative formulation.
- Alternative routes of administration.
- Use of combination products to reduce safety risks.
• Approaches to novel mechanisms to fulfil unmet needs.
• Driving renewed investment in novel target space and emergence of novel treatment modalities.
Dic Williams
Research Fellow, Pain Therapeutics Pfizer
16:30 Spinal cord stimulation for chronic pain.
• Spinal cord stimulation (SCS): An evidence-based therapy for the management of persisting pain.
• Review on the efficacy and effectiveness of spinal cord stimulation in relieving certain kinds of pain.
• Good indications for SCS.
17:10 Chair’s closing remarks.
17:20 End of conference.
For more information visit
http://www.bharatbook.com/detail.asp?id=134329&rt=Conference-on-7th-Annual-Pain-Management.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Accelerating innovation in drugs and devices for successful pain management
18th – 19th October 2010, BSG House, London, UK
Background Info
Key Speakers
• Theo F. Meert, Senior Research Fellow, Neuroscience, Johnson & Johnson
• Iain Chessell, VP Neuroscience, MedImmune
• Steve England, Associate Research Fellow, Pfizer
• Anne Estrup Olesen, Mech-Sense, Department of Gastroenterology,Aalborg University
• Anastasia Liapi, Director Business Development & New Product Leader CNS & Pain, Astellas
Extensive availability of generic drugs, pipeline products and increasing demand for efficient medical devices has accelerated growth of the global pain management marketplace. However recent issues involving patent expiries of top NSAID’s drugs, regulatory approvals and safety of analgesics classes are posing a huge challenge to this sector. How rapid will the pain management market grow in the next 10 years? What are the evolving segments of pain management and which new drugs in the pipeline will take the leap?
Join us at 7th Annual Pain Management Conference, where our expert panel of speakers, will share insights on ‘first-to-market’ opportunities, pivotal to achieve success in the global pain market across drugs and devices. With a special spotlight on innovations in analgesics, pipeline drugs and clinical breakthrough for chronic pain therapies, the conference will be an unmissable opportunity to maximise your knowledge and network with diverse industry leaders from the pain management sector.
Learn, exchange ideas and acquire knowledge on:
• Maximising the role of opioids in treatment of persistent pain
• Assessing the market dynamics of chronic pain and key pipeline development
• Gaining new insights into migraine pain and the molecular basis of effective therapeutics
• Developing spinal cord stimulation (SCS) for chronic pain of neuropathic
• Evaluating analgesic effect in experimental visceral pain models through translational pain research
• Examining pathophysiology of cancer pain and opioid tolerance
• Understanding the role of voltage-gated sodium channels in neuropathic pain
• Implementing target nerve growth factor (NGF) for pain therapy
• Devising a new methodology to measure quality of recovery from anaesthesia
• Developing a two step approach for treating diabetic neuropathy: eliminating the cause and relieving the symptoms
• Reviewing novel mechanisms for future pain therapies
Who should attend?
Presidents, CEOs, Vice-Presidents, CSOs, Directors, Senior Business Developers, Researchers and Professors in:
• Analgesia
• Pain Therapies/Research
• Neurosciences/ Neuropharmacology/ Neurology
• CNS Clinical Discovery/Nervous System Research
• Arthritis
• Migraine
• Drug Discovery
• Emerging Targets/Lead Optimisation
• Therapeutics and Molecular Profiling
• Pre-Clinical/Clinical R&D
• Genomics/Proteomics/Bioinformatics/Neuroinformatics
• Translational Medicine
• Imaging
• Regulatory Affairs
• Business Development
• Licensing and External Research
• Quality Control/Assurance
• Global Marketing and Medicine
Day 1
7th Annual Pain Management
Monday 18th October 2010
09:30 Registration and refreshments.
10:00 Opening address from the chair.
Chas Bountra
Chief Scientist, Structural Genomics Consortium, University of Oxford
10:10 A world of pain: Current and future market dynamics.
• Market dynamics in key pain indications and emerging trends.
• Changes in industrial landscape during the last year: Who is still standing and new kids on the block?
• Commercial considerations during drug development: R&D with the end in mind.
Anastasia Liapi
Director, Business Development Astellas
10:50 Developing a two step approach for treating diabetic neuropathy: Eliminating the cause and relieving the symptoms.
• Management of symptomatic diabetic sensory neuropathy: A therapeutic challenge.
• Using Aanticonvulsant and antiarrhythmic agents, and opioid-like medications.
• Topical therapies and non pharmalogic approaches.
• Recent advances in the diagnosis and management of diabetic neuropathy.
Dr James Campbell
CEO, Arcion Therapeutics
Professor, Department of Neurosurgery, School of Medicine Johns Hopkins University
11:30 Morning refreshments.
11:50 The use of biologic therapies for pain management: The next revolution?
• Review on how biologic therapies accelerate pain management: An analysis of preliminary data.
• Evaluating mAbs over traditional therapies: Target engagement, on- versus off-target tolerability profiles and potency/affinity.
• Examining the pros and cons of biologic therapies for pain.
• Current and future directions in pain management through biologic therapies.
Iain Chessell
Vice President, Neuroscience MedImmune
12:30 Voltage-gated sodium channels in neuropathic pain.
• What happens to sodium channels following peripheral nerve damage?
• What do the preclinical models tell us?
• If we find the right sodium channel modulator, will it work in the clinic?
• Future perspectives.
Steve England
Associate Research Fellow Pfizer
13:10 Networking lunch.
14:10 Evaluating analgesic effect in experimental visceral pain models through translational pain research.
• Assessing the challenges in pathophysiology of deep visceral pain.
• Optimising treatment and improving knowledge of the mechanisms and mode of action of analgesic substances.
• Experimental human visceral pain research for evaluation of analgesic action.
• Bridging the gap for translational pain research.
Anne Estrup Olesen
Mech-Sense, Department of Gastroenterology Aalborg University
14:50 What is the impact of chromatin modifications on establishing chronic pain state?
• Role of early life experiences.
• Can these changes be modulated to deliver new therapies?
• Will they be superior targets for drug discovery?
• Potential targets.
Chas Bountra
Chief Scientist, Structural Genomics Consortium, University of Oxford
15:30 Afternoon refreshments.
15.50 NSAIDs for Pain management: Safety and efficacy of NSAIDs.
NSAIDs are among the most common pain relievers in the world. And lately, they’re among the most controversial. Through this panel a discussion we will discuss the benefits and risks of NSAIDs.
16:30 Exploiting cannabinoids for pain relief: Current and emerging pharmacological strategies.
• Current strategy for targeting cannabinoid receptors.
• Emerging strategies for targeting cannabinoid receptors.
• Results from clinical trials.
17:10 Closing remarks from the chair.
17:20 Networking drinks.
Take your discussions further and build new relationships in a relaxed and informal setting.
Day 2
7th Annual Pain Management
Tuesday 19th October 2010
09:30 Registration and refreshments.
10:00 Opening address from the Chair.
Dr Dic Williams
Research Fellow, Pain Therapeutics Pfizer
10:10 Development of treatments for peripheral neuropathies.
• Existing treatment options.
• Preclinical research.
• Growth factors.
• POC modeling in humans.
Theo F Meert
Professor, Katholieke Universiteit Leuven and University of Antwerp
Senior Research Fellow, Neuroscience Johnson and Johnson
10:50 Human experimental pain models in early drug development.
• Translation from animal to human pain models.
• Back-translation from human models to animal models.
• Translating from human experimental pain models in volunteers to pain patients.
• Mechanisms based proof-of-concept studies.
• The concept of multi-model, multi-tissue pain models.
• Integrating pain models in phase Ib studies.
Prof Anthony Jones
Professor of Neuro-rheumatology,
Human Pain Research Group University of Manchester
11:30 Morning refreshments.
11:50 Advancements and emerging therapies for neuropathic pain.
• Emerging therapies for neuropathic pain.
• Current challenges: High unmet medical needs for new treatments with better efficacy and improved tolerability.
• Investigation of novel targets.
Jonathan Stewart
Honorary Consultant, Pain Medicine St Mary’s Hospital
12:30 What is the impact of chromatin modifications on establishing chronic pain state?
• Role of early life experiences.
• Can these changes be modulated to deliver new therapies?
• Will they be superior targets for drug discovery?
• Potential targets.
Chas Bountra
Chief Scientist, Structural Genomics Consortium University of Oxford
13:10 Networking lunch.
14:10 Cannabinoids and opioids: Case for synergy.
• Pharmacologic basis for a positive interaction.
• Animal studies.
• Clinical study concept validation.
Stephen Wright
Research and Development Director GW Pharmaceuticals
Prof Roger Pertwee
Professor of Neuropharmacology University of Aberdeen
14:50 Development of novel NSAIDs and COX-2 inhibitors in the post-Vioxx era.
• What have we learned about GI and cardiovascular risk?
• What strategies are being employed to improve GI and cardiovascular safety?
- Example #1: Naproxcinod, a nitric-oxide donating analog of naproxen.
- Example #2: CG100649, a dual inhibitor of COX-2 and carbonic anhydrase.
• Are regulatory hurdles manageable in the USA and Europe?
15:30 Afternoon refreshments.
15.50 Future pain management: emerging new mechanisms and modalities.
• Overview of the established pain relief mechanisms: Non-steroidal anti-inflammatory and opiates.
• Maximising therapeutic benefit and efficacy of pain relief mechanisms.
- Development of innovative formulation.
- Alternative routes of administration.
- Use of combination products to reduce safety risks.
• Approaches to novel mechanisms to fulfil unmet needs.
• Driving renewed investment in novel target space and emergence of novel treatment modalities.
Dic Williams
Research Fellow, Pain Therapeutics Pfizer
16:30 Spinal cord stimulation for chronic pain.
• Spinal cord stimulation (SCS): An evidence-based therapy for the management of persisting pain.
• Review on the efficacy and effectiveness of spinal cord stimulation in relieving certain kinds of pain.
• Good indications for SCS.
17:10 Chair’s closing remarks.
17:20 End of conference.
For more information visit
http://www.bharatbook.com/detail.asp?id=134329&rt=Conference-on-7th-Annual-Pain-Management.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Conference on CNS Clinical Trials
Conference on CNS Clinical Trials
Optimising development, management and recruitment for clinical trials in CNS
16th - 17th September 2010, BSG Conference Centre, London, UK
Background Info
Key Speakers
Dr Erik Buntinx, Managing Director and Chief Scientifi c Offi cer, PharmaNeuroBoost
Dr Samuel Agus, Global Medical Affairs Director, Neurology, Solvay Pharmaceuticals Marketing and Licensing
Dr Stig Johan Wiklund, Statistical Science Director, AstraZeneca R&D
Dr Fabrizio Gasparini, Sr Research Investigator, Novartis Institutes for BioMedical Research
Dr Mark Tricklebank Director, Senior Research Fellow - Psychiatric Disorders Drug Hunting Team, Lilly
Dr Simone Braggio, Director Neurosciences CEDD DMPK, GlaxoSmithKline
Dr Karl Herholz Director, Wolfson Molecular Imaging Centre/ Professor of Clinical Neuroscience, University of Manchester
Professor Elaine Rankin, Medical Oncology, University of Dundee
Professor Alan M Palmer, Chief Scientifi c Offi cer, MS Therapeutics
Nancy Mulligan, VP, CNS / Mental Health, MMG
Professor Mehdi Adineh, Scientifi c Director Diagnostic Imaging Core Laboratory, American College of
Radiology Imaging Network (ACRIN)
CNS is one of the largest and fastest growing therapeutic areas of the
pharmaceutical market. The ageing of the baby-boom generation combined
with new and emerging treatments for neurodegenerative disorders, including multiple sclerosis, Alzheimer’s disease and Parkinson’s disease, will lead to further expansion of the neurodegenerative therapies market.
CNS Clinical Trials conference you will examine the strategies offering
the greatest potential for success in CNS drug development, and understand the specifi c
challenges currently faced by developers in this market. In order to enhance productivity
in this fi eld, there has been an increased awareness of the need to align clinical and
preclinical research to facilitate rapid development of new CNS drug therapies. Medical
imaging is increasingly being used as a surrogate endpoint or biomarker of drug effi cacy
in all phases of CNS trials, enabling CNS developers to make more timely decisions.
By attending this conference you will:
• Examine novel approaches for assessing cognitive function
• Explore the latest advances in neuroimaging
• Develop effective methods for improved patient recruitment and retention
• Understand statistical thinking for designing adaptive trials
• Review Good Clinical Practice GCP guidelines
• Address the regulatory challenges for CNS drug approval
• Utilise biomarkers for Proof of Concept in CNS clinical trials
• Improve trial outcomes through increased communication, ethical consent and
patient care
• Implement translational methods to bridge the gap between pre-clinical and clinical
CNS trials
• Be part of a major networking opportunity
Target Audience:
• Pharmaceutical and biotech companies
• Clinical research organisations
• Regulatory agencies/ associations
Who will be there?
Senior VPs, VPs, Chief Scientifi c Offi cers, Directors, Heads and
Managers of:
• CNS Trials
• Clinical Trials
• Clinical Research & Development
• Clinical Operations
• CNS
• CNS Clinical Biomarker Group
• Clinical Pharmacology
• Neurobiology
• Neuromedical Oncology
• Neurology/ Neuroscience Research
• Psychiatry
• Psychology
• CNS Ageing Research
• Dementia
• Imaging/ Neuroimaging
• Movement Disorders
• CNS Global Marketing & Medicine
• Preclinical R&D
• Translational Medicine
• Biostatistics
• Experimental Therapeutics
• Clinical Technology
• Outcomes Research
• Regulatory Affairs
• Product Development
Day 1,Monday 16th March 2010, London, UK
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 The discovery and development of CNS medicines
• Progress in CNS medicines research
• Market landscape
• The challenges for CNS R&D
• Future prospects
Professor Alan M Palmer
Chief Scientific Officert
MS Therapeutics
10:50 Addressing specific challenges arising in the clinical trials of neuroprotective agents
11:30 Morning refreshments
11:50 Clinical value of accelerated anti-depressant effect
• Lag time of antidepressants: an unmet medical need
• Early and Sustained Full Response: A new FDA approved
efficacy paradigm
• Pharmacological considerations to induce accelerated
antidepressant effect
• Treatment adherence in relation to an antidepressant with an
accelerated effect
Dr Erik Buntinx
Managing Director and Chief Scientific Officer
PharmaNeuroBoost
12:30 Considerations for design and statistical analysis
of CNS trials
• Analysis and design for disease modification
• Missing data issues
• Adaptive design issues when applied in CNS trials
Dr Stig Johan Wiklund
Statistical Science Director
AstraZeneca R&D
13:10 Networking Lunch
14:30 mGluR5 Allosteric Antagonists: Preclinical profile and choice of therapeutic indication
• Characterization of mGluR5 antagonist in preclinical paradigm
• Validation of objective markers for monitoring drug action
• Use of preclinical profiling and proof-of-concept clinical trials to
select therapeutic indications for full development
Dr Fabrizio Gasparini
Sr Research Investigator Novartis Institutes for BioMedical Research
15:10 Suicidality: Ensuring quality in mandated prospective monitoring
• Overview of the Columbia-Suicide Severity Rating Scale (C-SSRS)
• Potential pitfalls with collection of suicidality monitoring data
• eC-SSRS - electronically modeling and reproducing the optimal
human interview
• eC-SSRS – meeting the goals of excellent science and clinical care
• eC-SSRS – a clinical trial case study
Dr John Greist
Distinguished Senior Scientist, Madison Institute of Medicine
Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health
15:50 Afternoon refreshments
16:10 CNS clinical trials beyond registration
• Trials beyond registration a tool for assessing a drug in real-life setting
• Types of post-registration studies, goals, deliverables and methods
• When should trials beyond registration begin?
• Life cycle management and drug safety- 2 sides for the same coin
• Who initiates investigator-initiated-trials and what is their purpose
Dr Samuel Agus
Global Medical Affairs Director, Neurology
Solvay Pharmaceuticals Marketing and Licensing
16:50 Closing remarks from the chair
Day2,Thursday 17th March 2010, London, UK
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Bridging the gap between pre-clinical and
clinical CNS trials
• Translational assays of cognition
• Animal models of cognitive impairment
• Use of preclinical biomarkers to enhance assay translation
• Clinical testing of preclinical hypotheses
Dr Mark Tricklebank
Director, Lilly Centre for Cognitive Neuroscience
Eli Lilly and Co
10:50 Reducing the gap between preclinical PK/PD and CNS clinical trials
• Adding value to the discovery of CNS active drugs through the application of mechanistic PK/PD principles
• Understanding the key drivers of in-vivo pharmacological effects and ensuring they are prominent in the lead optimisation paradigm
• Establishing the link between blood concentration, receptor occupancy and drug efficacy
11:30 Morning refreshments
11:50 Novel imaging approaches in clinical trials and the role of an imaging CRO
• Novel Imaging Approaches including Structural, Functional and Molecular in CNS Drug Discovery including PET, DTI, fMRI and vCT.
• Imaging Drug Actions Including Neuroreceptor Mapping
• The role of an Imaging CRO in Managing an Imaging Clinical Trial
Professor Mehdi Adineh
Scientific Director Diagnostic Imaging Core Laboratory
American College of Radiology
12:30 Utilising PET imaging biomarkers
• Dementia: glucose metabolism, amyloid tracers, acetylcholine analogues
• Parkinson’s disease: dopamine synthesis & storage capacity
• Psychiatric disorders: dopamine & serotonin receptor occupancy
• Brain tumours: progression and infiltration
• Tracers and techniques for quantitative standardised analysis will be presented
Dr Karl Herholz
Director, Wolfson Molecular Imaging Centre/ Professor of
Clinical Neuroscience
University of Manchester
13:10 Networking Lunch
14.10 Use of biomarkers for demonstrating CNS effects of drugs early in clinical development
• Using animal PK/PD data to set dose range finding in Phase 1
• Use of QEEG to demonstrate CNS activity
• Computer measures of cognition
• Evoked potentials to demonstrate clinical potential
Dr. Michael G. Palfreyman
Head, Translational R&D, ChemDiv
Executive Program Director, Senior Scientific Advisor, EnVivo Pharmaceuticals
14:50 Recruiting strategies for Huntington’s Disease
clinical trials
• The importance of identifying unique barriers to participation in HD clinical trials
• Grass-roots social marketing for HD trials can speed enrollment:
a pilot study
• Treating the HD trial participant as VIP is a cost-effective approach.
Dr LaVonne Veatch Goodman
Co-founder
Huntington’s Disease Drug Works (HDDW)
15:30 Afternoon refreshments
15:50 Patient recruitment and retention strategies for
CNS clinical trials
• Patient population insights that need to be considered in designing recruitment and retention programs for CNS trials
• Strategies for overcoming global CNS patient recruitment challenges
• Updates on evolving trends in patient recruitment and retention methodologies
• Illustrative case studies of effective tactics
Gaynor Anders
Vice President Global Operations
MMG
16.30 Successful strategies for accelerating
patient recruitment
• Preparing for successful enrolment
• The ideal set-up
• Avoiding the pitfalls for a pharma-driven trial
• Enlisting support from patients
Professor Elaine Rankin
Medical Oncology
University of Dundee
17:10 Chair’s closing remarks
17:20 End of conference
Related Reports:
Clinical Trials Market India
Clinical Trials: World Market 2009-2024
Emerging Clinical Trial Locations: Market dynamics and the changing healthcare and regulatory environment
Trends in Clinical Trials Strategies to enhance clinical trial design
Medical Device Clinical Trials Destination India
For more information visit
http://www.bharatbook.com/detail.asp?id=128073&rt=Conference-on-CNS-Clinical-Trials.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Optimising development, management and recruitment for clinical trials in CNS
16th - 17th September 2010, BSG Conference Centre, London, UK
Background Info
Key Speakers
Dr Erik Buntinx, Managing Director and Chief Scientifi c Offi cer, PharmaNeuroBoost
Dr Samuel Agus, Global Medical Affairs Director, Neurology, Solvay Pharmaceuticals Marketing and Licensing
Dr Stig Johan Wiklund, Statistical Science Director, AstraZeneca R&D
Dr Fabrizio Gasparini, Sr Research Investigator, Novartis Institutes for BioMedical Research
Dr Mark Tricklebank Director, Senior Research Fellow - Psychiatric Disorders Drug Hunting Team, Lilly
Dr Simone Braggio, Director Neurosciences CEDD DMPK, GlaxoSmithKline
Dr Karl Herholz Director, Wolfson Molecular Imaging Centre/ Professor of Clinical Neuroscience, University of Manchester
Professor Elaine Rankin, Medical Oncology, University of Dundee
Professor Alan M Palmer, Chief Scientifi c Offi cer, MS Therapeutics
Nancy Mulligan, VP, CNS / Mental Health, MMG
Professor Mehdi Adineh, Scientifi c Director Diagnostic Imaging Core Laboratory, American College of
Radiology Imaging Network (ACRIN)
CNS is one of the largest and fastest growing therapeutic areas of the
pharmaceutical market. The ageing of the baby-boom generation combined
with new and emerging treatments for neurodegenerative disorders, including multiple sclerosis, Alzheimer’s disease and Parkinson’s disease, will lead to further expansion of the neurodegenerative therapies market.
CNS Clinical Trials conference you will examine the strategies offering
the greatest potential for success in CNS drug development, and understand the specifi c
challenges currently faced by developers in this market. In order to enhance productivity
in this fi eld, there has been an increased awareness of the need to align clinical and
preclinical research to facilitate rapid development of new CNS drug therapies. Medical
imaging is increasingly being used as a surrogate endpoint or biomarker of drug effi cacy
in all phases of CNS trials, enabling CNS developers to make more timely decisions.
By attending this conference you will:
• Examine novel approaches for assessing cognitive function
• Explore the latest advances in neuroimaging
• Develop effective methods for improved patient recruitment and retention
• Understand statistical thinking for designing adaptive trials
• Review Good Clinical Practice GCP guidelines
• Address the regulatory challenges for CNS drug approval
• Utilise biomarkers for Proof of Concept in CNS clinical trials
• Improve trial outcomes through increased communication, ethical consent and
patient care
• Implement translational methods to bridge the gap between pre-clinical and clinical
CNS trials
• Be part of a major networking opportunity
Target Audience:
• Pharmaceutical and biotech companies
• Clinical research organisations
• Regulatory agencies/ associations
Who will be there?
Senior VPs, VPs, Chief Scientifi c Offi cers, Directors, Heads and
Managers of:
• CNS Trials
• Clinical Trials
• Clinical Research & Development
• Clinical Operations
• CNS
• CNS Clinical Biomarker Group
• Clinical Pharmacology
• Neurobiology
• Neuromedical Oncology
• Neurology/ Neuroscience Research
• Psychiatry
• Psychology
• CNS Ageing Research
• Dementia
• Imaging/ Neuroimaging
• Movement Disorders
• CNS Global Marketing & Medicine
• Preclinical R&D
• Translational Medicine
• Biostatistics
• Experimental Therapeutics
• Clinical Technology
• Outcomes Research
• Regulatory Affairs
• Product Development
Day 1,Monday 16th March 2010, London, UK
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 The discovery and development of CNS medicines
• Progress in CNS medicines research
• Market landscape
• The challenges for CNS R&D
• Future prospects
Professor Alan M Palmer
Chief Scientific Officert
MS Therapeutics
10:50 Addressing specific challenges arising in the clinical trials of neuroprotective agents
11:30 Morning refreshments
11:50 Clinical value of accelerated anti-depressant effect
• Lag time of antidepressants: an unmet medical need
• Early and Sustained Full Response: A new FDA approved
efficacy paradigm
• Pharmacological considerations to induce accelerated
antidepressant effect
• Treatment adherence in relation to an antidepressant with an
accelerated effect
Dr Erik Buntinx
Managing Director and Chief Scientific Officer
PharmaNeuroBoost
12:30 Considerations for design and statistical analysis
of CNS trials
• Analysis and design for disease modification
• Missing data issues
• Adaptive design issues when applied in CNS trials
Dr Stig Johan Wiklund
Statistical Science Director
AstraZeneca R&D
13:10 Networking Lunch
14:30 mGluR5 Allosteric Antagonists: Preclinical profile and choice of therapeutic indication
• Characterization of mGluR5 antagonist in preclinical paradigm
• Validation of objective markers for monitoring drug action
• Use of preclinical profiling and proof-of-concept clinical trials to
select therapeutic indications for full development
Dr Fabrizio Gasparini
Sr Research Investigator Novartis Institutes for BioMedical Research
15:10 Suicidality: Ensuring quality in mandated prospective monitoring
• Overview of the Columbia-Suicide Severity Rating Scale (C-SSRS)
• Potential pitfalls with collection of suicidality monitoring data
• eC-SSRS - electronically modeling and reproducing the optimal
human interview
• eC-SSRS – meeting the goals of excellent science and clinical care
• eC-SSRS – a clinical trial case study
Dr John Greist
Distinguished Senior Scientist, Madison Institute of Medicine
Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health
15:50 Afternoon refreshments
16:10 CNS clinical trials beyond registration
• Trials beyond registration a tool for assessing a drug in real-life setting
• Types of post-registration studies, goals, deliverables and methods
• When should trials beyond registration begin?
• Life cycle management and drug safety- 2 sides for the same coin
• Who initiates investigator-initiated-trials and what is their purpose
Dr Samuel Agus
Global Medical Affairs Director, Neurology
Solvay Pharmaceuticals Marketing and Licensing
16:50 Closing remarks from the chair
Day2,Thursday 17th March 2010, London, UK
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Bridging the gap between pre-clinical and
clinical CNS trials
• Translational assays of cognition
• Animal models of cognitive impairment
• Use of preclinical biomarkers to enhance assay translation
• Clinical testing of preclinical hypotheses
Dr Mark Tricklebank
Director, Lilly Centre for Cognitive Neuroscience
Eli Lilly and Co
10:50 Reducing the gap between preclinical PK/PD and CNS clinical trials
• Adding value to the discovery of CNS active drugs through the application of mechanistic PK/PD principles
• Understanding the key drivers of in-vivo pharmacological effects and ensuring they are prominent in the lead optimisation paradigm
• Establishing the link between blood concentration, receptor occupancy and drug efficacy
11:30 Morning refreshments
11:50 Novel imaging approaches in clinical trials and the role of an imaging CRO
• Novel Imaging Approaches including Structural, Functional and Molecular in CNS Drug Discovery including PET, DTI, fMRI and vCT.
• Imaging Drug Actions Including Neuroreceptor Mapping
• The role of an Imaging CRO in Managing an Imaging Clinical Trial
Professor Mehdi Adineh
Scientific Director Diagnostic Imaging Core Laboratory
American College of Radiology
12:30 Utilising PET imaging biomarkers
• Dementia: glucose metabolism, amyloid tracers, acetylcholine analogues
• Parkinson’s disease: dopamine synthesis & storage capacity
• Psychiatric disorders: dopamine & serotonin receptor occupancy
• Brain tumours: progression and infiltration
• Tracers and techniques for quantitative standardised analysis will be presented
Dr Karl Herholz
Director, Wolfson Molecular Imaging Centre/ Professor of
Clinical Neuroscience
University of Manchester
13:10 Networking Lunch
14.10 Use of biomarkers for demonstrating CNS effects of drugs early in clinical development
• Using animal PK/PD data to set dose range finding in Phase 1
• Use of QEEG to demonstrate CNS activity
• Computer measures of cognition
• Evoked potentials to demonstrate clinical potential
Dr. Michael G. Palfreyman
Head, Translational R&D, ChemDiv
Executive Program Director, Senior Scientific Advisor, EnVivo Pharmaceuticals
14:50 Recruiting strategies for Huntington’s Disease
clinical trials
• The importance of identifying unique barriers to participation in HD clinical trials
• Grass-roots social marketing for HD trials can speed enrollment:
a pilot study
• Treating the HD trial participant as VIP is a cost-effective approach.
Dr LaVonne Veatch Goodman
Co-founder
Huntington’s Disease Drug Works (HDDW)
15:30 Afternoon refreshments
15:50 Patient recruitment and retention strategies for
CNS clinical trials
• Patient population insights that need to be considered in designing recruitment and retention programs for CNS trials
• Strategies for overcoming global CNS patient recruitment challenges
• Updates on evolving trends in patient recruitment and retention methodologies
• Illustrative case studies of effective tactics
Gaynor Anders
Vice President Global Operations
MMG
16.30 Successful strategies for accelerating
patient recruitment
• Preparing for successful enrolment
• The ideal set-up
• Avoiding the pitfalls for a pharma-driven trial
• Enlisting support from patients
Professor Elaine Rankin
Medical Oncology
University of Dundee
17:10 Chair’s closing remarks
17:20 End of conference
Related Reports:
Clinical Trials Market India
Clinical Trials: World Market 2009-2024
Emerging Clinical Trial Locations: Market dynamics and the changing healthcare and regulatory environment
Trends in Clinical Trials Strategies to enhance clinical trial design
Medical Device Clinical Trials Destination India
For more information visit
http://www.bharatbook.com/detail.asp?id=128073&rt=Conference-on-CNS-Clinical-Trials.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Conference on Vaccine Research & Innovation 2010
Key Speakers
Guido Grandi, Senior Project Leader, Novartis Vaccines and Diagnostics
Dr Bassam Hallis, General Project Manager, Centre for Emergency Preparedness and Response, Health Protection Agency
Alexander von Gabain, Founder & Strategic Advisor to the Management and Supervisory Boards, Intercell
Dr David Kirke, Associate Director of Regulatory Affairs, ERA Consulting
Dr Barbara Guinn, Cancer Sciences Division, University of Southampton
Jean Marc Balloul, New Venture Development Director, Transgene
Lior Carmon, Founder & CEO, Vaxil Biotherapeutics
Conference Introduction
Vaccine Research & Innovation 2010
2nd – 3rd September 2010
Dear Colleague,
Increasing use of novel technologies has boosted the vaccines industry worldwide. Recent technological breakthroughs in vaccine research, manufacturing and delivery, promise a bright future for the new generation of vaccines, particularly for chronic conditions such as cancer, auto-immune diseases and nicotine addiction. According to recent report, The Global Vaccines Market, 2008-2023, therapeutic vaccines will significantly expand the vaccines market contributing to rapid revenue growth during the period 2008 to 2023. The cancer vaccine market, led by cervical cancer vaccines, is presently one of the most lucrative areas for vaccine manufacturers. Advances are also being made in almost all adjunct areas of vaccine research, such as the mode of delivery, use of combination vaccines, vaccine adjuvant, and vaccine manufacturing. Our Vaccine Research & Innovation conference is designed to implement successful strategies and innovative technologies to develop more effective vaccines. Gain insights through industry led case studies and discussions with key decision markers from the vaccines sector. Network and collaborate with global professionals to keep up-to-date with future trends and exploring business opportunities at the two-day event.
By attending this conference you will gain insights on:
• Overcoming challenges to cancer vaccine development
• Evaluating the immune response to combination vaccines
• Accelerating new vaccine introduction in the developing world
• Monitoring High sensitivity T cell immune mechanism of novel vaccines, gene therapy, protein based drugs
• Assessing the key immunological observations on clinical development of pandemic influenza A (H1N1) vaccines
• Examining the safety challenges on new vaccine introduction
• Implementing strategies for manufacturing and purification of conjugate vaccines
• Good supply chain management practices for vaccine distribution
Who will be there?
Presidents, Chief Executives, VPs, Global Heads, Scientific Advisors, Therapeutic Area Heads, in:
• Vaccine equipment and manufacturing
• Vaccine application development
• Vaccinology and molecular biology
• Cell line engineering
• Proteomics, recombinant protein/DNA biotechnology
• Infectious disease R&D
• In-licensing and out-licensing
• Pharmacovigilance and safety testing
• Regulatory affairs
• Strategic product development
• External research
• Manufacturing/production
• Chemistry manufacturing and controls (CMC)
• Procurement & purchasing
• Cold chain supply and lyophilisation
• Strategic alliances
• Clinical product resourcing
• Supply outsourcing project management
• Contract management
• Process development
• Business development
• Drug discovery & delivery
• Patent law
• Investment and venture capital
Sponsorship and exhibition opportunities:
This event offers a unique opportunity to meet and do business with some of the key players in the pharmaceutical and biotech industries. If you have a service or product to promote, you can do so at this event by:
• Hosting a networking drinks reception
• Taking an exhibition space at the conference
• Advertising in the delegate documentation pack
• Providing branded bags, pens, gifts, etc.
If you would like more information on the range of sponsorship or exhibition possibilities for Vaccine Innovation and Cell Line Development Conference, please contact us:
Phone: +91 22 27578668
Email : raju@bharatbook.com
Day 1
Vaccine Research & Innovation 2010
Thursday 2nd September 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Regulatory challenges in the approval process for novel vaccine adjuvants
• Regulation and evaluation process of new adjuvants in vaccines
• Differences in the global regulatory requirements and overcoming
these challenges
• Engaging with regulators and contributing to the evolution of
regulatory framework
• Integrating your global regulatory strategy and product development
plan
Dr. David Kirke
Associate Director - Regulatory Affairs
ERA Consulting
10:50 Evaluating the immune response to combination vaccines
• High sensitivity T cell immune monitoring of novel vaccines, gene therapy, protein based drugs
• Immune monitoring during pre clinical and clinical trials to detect adverse immune reactions to gene therapy and protein based drugs early
Dr Thomas O Kleen
Director, Business and Technology Development
Cellular Technology
11:30 Morning refreshments
11:50 High-throughput stable cell line generation
• Current-generation high-throughput sequencing
• Establishing new assays for high-throughput screening
• Optimised system for rapid generation of localisation and affinity purification-tagged mammalian stable cell lines
• Stabilisation of cell lines
12.30 Development of avian cell lines dedicated to vaccines manufacturing
• Human vaccine (Flu, Flavivirus, Recombinant Poxvirus)
• Veterinary vaccine
• Therapeutic proteins
Jean Marc Balloul
New Venture Development Director
Transgene
13:10 Networking lunch
14.10 Biologics cell line and process development
• Investigating a range of cell culture parameters
• Cell line selection and delivery system
• Vector redesign to improve cell line stability and clone selection
• Automation processes for cell line development
Karl Kreij
Cell Culture Scientist
Crucell
14:50 Manufacturing and purification strategies of conjugate vaccines
• Conjugate vaccine (peptide/chemical hapten) development, optimisation and production
• Production issues for conjugate vaccines
• Overview of the novel purification approaches
• Downstream processing parameters for purification
• Analysing the challenges associated with purification procedures
• Wide-scale adoption of disposable technologies
15:30 Afternoon refreshments
15:50 Safety monitoring in vaccine development and immunisation
• How can you know vaccines are safe?
• Challenges and risks with new vaccine introduction
• Surveillance through clinical trials to manufacturing processes
• Vaccine Adverse Event Reporting System (VAERS)
16:30 Challenges to cancer vaccine development
• Overview of the main immune responses
• Identifying targets for immune therapy
• New vaccine development and current clinical trials
Dr. Barbara Guinn
Cancer Sciences Division
University of Southampton
17:10 Closing remarks from the chair
17:20 Networking drinks
Take your discussions further and build new
relationships in a relaxed and informal setting.
Day 2
Vaccine Research & Innovation 2010
Friday 3rd September 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Development of a pneumococcal vaccine comprising highly conserved proteins
• Discovery of a novel class of highly conserved vaccine antigens
• Approach for new-generation vaccines is the use of nonpolysaccharide antigens that are conserved among pneumococcal strains
• Changing epidemiology of pneumococcal infection
•Immunological considerations and correlates
Alexander von Gabain
Founder & Strategic Advisor to the Management and Supervisory Boards
Intercell
10:50 From trial and error to rational design of adjuvant vaccines
• Adjuvant need not induce side effects: A different concept
• ISCOM, adjuvant for newborns and elderly
• Antigen sparing an essential aspect
• Broadening of immune response
Bror Morein
Department of Medical Sciences, Virology, Uppsala University
Chairman of the Scientific Advisory Board, Isconova
11:30 Morning refreshments
11:50 Case Study: Key immunological observations on clinical development of pandemic influenza A (H1N1) vaccines
Dr. Bassam Hallis
General Project Manager
Centre for Emergency Preparedness and Response
Health Protection Agency
12:30 Vaccine development & early clinical research
(Phase I)
• Phase I study design
• Managing sponsors
• Managing the vaccines
•Operational execution
Andrew Nolan
Senior Project Manager
Phase I Therapeutic Area Head – Vaccines
Quintiles
13:10 Networking lunch
14:10 Case study: Developing the next generation of therapeutic vaccines
The case study will feature novel, therapeutic vaccines for the treatment of cancer and key intracellular pathogens via specific manipulation and augmentation of the patient cellular immune responses.
Lior Carmon
Founder & CEO
Vaxil Biotherapeutics
14:50 Surface proteome analysis as a fast-track to vaccine discovery
• Stripping away cell-surface proteins
• Mass-spectrometry and in silico surfome analysis
• Identification and validation of new targets for group A Streptococcus
Guido
Grandi
Senior Project Leader
Novartis Vaccines and Diagnostics
15:30 Afternoon refreshments
15:50 Challenges in adult immunisation
• What are disease areas in adult immunisation?
• Implementation of strategies to improve vaccination coverage
• Indentifying and minimising the impact on accessibility and affordability of adult vaccines
16.30 Accelerating new vaccine introduction in the developing world
• Meeting the challenges in introducing new vaccines: Logistics, supply and quality control issues
• Overcoming shortage and delays
• Good supply chain management practices for vaccine distribution
17:10 Chair’s closing remarks
17:20 End of Conference
For more information visit
http://www.bharatbook.com/detail.asp?id=133389&rt=Conference-on-Vaccine-Research-Innovation-2010.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Guido Grandi, Senior Project Leader, Novartis Vaccines and Diagnostics
Dr Bassam Hallis, General Project Manager, Centre for Emergency Preparedness and Response, Health Protection Agency
Alexander von Gabain, Founder & Strategic Advisor to the Management and Supervisory Boards, Intercell
Dr David Kirke, Associate Director of Regulatory Affairs, ERA Consulting
Dr Barbara Guinn, Cancer Sciences Division, University of Southampton
Jean Marc Balloul, New Venture Development Director, Transgene
Lior Carmon, Founder & CEO, Vaxil Biotherapeutics
Conference Introduction
Vaccine Research & Innovation 2010
2nd – 3rd September 2010
Dear Colleague,
Increasing use of novel technologies has boosted the vaccines industry worldwide. Recent technological breakthroughs in vaccine research, manufacturing and delivery, promise a bright future for the new generation of vaccines, particularly for chronic conditions such as cancer, auto-immune diseases and nicotine addiction. According to recent report, The Global Vaccines Market, 2008-2023, therapeutic vaccines will significantly expand the vaccines market contributing to rapid revenue growth during the period 2008 to 2023. The cancer vaccine market, led by cervical cancer vaccines, is presently one of the most lucrative areas for vaccine manufacturers. Advances are also being made in almost all adjunct areas of vaccine research, such as the mode of delivery, use of combination vaccines, vaccine adjuvant, and vaccine manufacturing. Our Vaccine Research & Innovation conference is designed to implement successful strategies and innovative technologies to develop more effective vaccines. Gain insights through industry led case studies and discussions with key decision markers from the vaccines sector. Network and collaborate with global professionals to keep up-to-date with future trends and exploring business opportunities at the two-day event.
By attending this conference you will gain insights on:
• Overcoming challenges to cancer vaccine development
• Evaluating the immune response to combination vaccines
• Accelerating new vaccine introduction in the developing world
• Monitoring High sensitivity T cell immune mechanism of novel vaccines, gene therapy, protein based drugs
• Assessing the key immunological observations on clinical development of pandemic influenza A (H1N1) vaccines
• Examining the safety challenges on new vaccine introduction
• Implementing strategies for manufacturing and purification of conjugate vaccines
• Good supply chain management practices for vaccine distribution
Who will be there?
Presidents, Chief Executives, VPs, Global Heads, Scientific Advisors, Therapeutic Area Heads, in:
• Vaccine equipment and manufacturing
• Vaccine application development
• Vaccinology and molecular biology
• Cell line engineering
• Proteomics, recombinant protein/DNA biotechnology
• Infectious disease R&D
• In-licensing and out-licensing
• Pharmacovigilance and safety testing
• Regulatory affairs
• Strategic product development
• External research
• Manufacturing/production
• Chemistry manufacturing and controls (CMC)
• Procurement & purchasing
• Cold chain supply and lyophilisation
• Strategic alliances
• Clinical product resourcing
• Supply outsourcing project management
• Contract management
• Process development
• Business development
• Drug discovery & delivery
• Patent law
• Investment and venture capital
Sponsorship and exhibition opportunities:
This event offers a unique opportunity to meet and do business with some of the key players in the pharmaceutical and biotech industries. If you have a service or product to promote, you can do so at this event by:
• Hosting a networking drinks reception
• Taking an exhibition space at the conference
• Advertising in the delegate documentation pack
• Providing branded bags, pens, gifts, etc.
If you would like more information on the range of sponsorship or exhibition possibilities for Vaccine Innovation and Cell Line Development Conference, please contact us:
Phone: +91 22 27578668
Email : raju@bharatbook.com
Day 1
Vaccine Research & Innovation 2010
Thursday 2nd September 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Regulatory challenges in the approval process for novel vaccine adjuvants
• Regulation and evaluation process of new adjuvants in vaccines
• Differences in the global regulatory requirements and overcoming
these challenges
• Engaging with regulators and contributing to the evolution of
regulatory framework
• Integrating your global regulatory strategy and product development
plan
Dr. David Kirke
Associate Director - Regulatory Affairs
ERA Consulting
10:50 Evaluating the immune response to combination vaccines
• High sensitivity T cell immune monitoring of novel vaccines, gene therapy, protein based drugs
• Immune monitoring during pre clinical and clinical trials to detect adverse immune reactions to gene therapy and protein based drugs early
Dr Thomas O Kleen
Director, Business and Technology Development
Cellular Technology
11:30 Morning refreshments
11:50 High-throughput stable cell line generation
• Current-generation high-throughput sequencing
• Establishing new assays for high-throughput screening
• Optimised system for rapid generation of localisation and affinity purification-tagged mammalian stable cell lines
• Stabilisation of cell lines
12.30 Development of avian cell lines dedicated to vaccines manufacturing
• Human vaccine (Flu, Flavivirus, Recombinant Poxvirus)
• Veterinary vaccine
• Therapeutic proteins
Jean Marc Balloul
New Venture Development Director
Transgene
13:10 Networking lunch
14.10 Biologics cell line and process development
• Investigating a range of cell culture parameters
• Cell line selection and delivery system
• Vector redesign to improve cell line stability and clone selection
• Automation processes for cell line development
Karl Kreij
Cell Culture Scientist
Crucell
14:50 Manufacturing and purification strategies of conjugate vaccines
• Conjugate vaccine (peptide/chemical hapten) development, optimisation and production
• Production issues for conjugate vaccines
• Overview of the novel purification approaches
• Downstream processing parameters for purification
• Analysing the challenges associated with purification procedures
• Wide-scale adoption of disposable technologies
15:30 Afternoon refreshments
15:50 Safety monitoring in vaccine development and immunisation
• How can you know vaccines are safe?
• Challenges and risks with new vaccine introduction
• Surveillance through clinical trials to manufacturing processes
• Vaccine Adverse Event Reporting System (VAERS)
16:30 Challenges to cancer vaccine development
• Overview of the main immune responses
• Identifying targets for immune therapy
• New vaccine development and current clinical trials
Dr. Barbara Guinn
Cancer Sciences Division
University of Southampton
17:10 Closing remarks from the chair
17:20 Networking drinks
Take your discussions further and build new
relationships in a relaxed and informal setting.
Day 2
Vaccine Research & Innovation 2010
Friday 3rd September 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Development of a pneumococcal vaccine comprising highly conserved proteins
• Discovery of a novel class of highly conserved vaccine antigens
• Approach for new-generation vaccines is the use of nonpolysaccharide antigens that are conserved among pneumococcal strains
• Changing epidemiology of pneumococcal infection
•Immunological considerations and correlates
Alexander von Gabain
Founder & Strategic Advisor to the Management and Supervisory Boards
Intercell
10:50 From trial and error to rational design of adjuvant vaccines
• Adjuvant need not induce side effects: A different concept
• ISCOM, adjuvant for newborns and elderly
• Antigen sparing an essential aspect
• Broadening of immune response
Bror Morein
Department of Medical Sciences, Virology, Uppsala University
Chairman of the Scientific Advisory Board, Isconova
11:30 Morning refreshments
11:50 Case Study: Key immunological observations on clinical development of pandemic influenza A (H1N1) vaccines
Dr. Bassam Hallis
General Project Manager
Centre for Emergency Preparedness and Response
Health Protection Agency
12:30 Vaccine development & early clinical research
(Phase I)
• Phase I study design
• Managing sponsors
• Managing the vaccines
•Operational execution
Andrew Nolan
Senior Project Manager
Phase I Therapeutic Area Head – Vaccines
Quintiles
13:10 Networking lunch
14:10 Case study: Developing the next generation of therapeutic vaccines
The case study will feature novel, therapeutic vaccines for the treatment of cancer and key intracellular pathogens via specific manipulation and augmentation of the patient cellular immune responses.
Lior Carmon
Founder & CEO
Vaxil Biotherapeutics
14:50 Surface proteome analysis as a fast-track to vaccine discovery
• Stripping away cell-surface proteins
• Mass-spectrometry and in silico surfome analysis
• Identification and validation of new targets for group A Streptococcus
Guido
Grandi
Senior Project Leader
Novartis Vaccines and Diagnostics
15:30 Afternoon refreshments
15:50 Challenges in adult immunisation
• What are disease areas in adult immunisation?
• Implementation of strategies to improve vaccination coverage
• Indentifying and minimising the impact on accessibility and affordability of adult vaccines
16.30 Accelerating new vaccine introduction in the developing world
• Meeting the challenges in introducing new vaccines: Logistics, supply and quality control issues
• Overcoming shortage and delays
• Good supply chain management practices for vaccine distribution
17:10 Chair’s closing remarks
17:20 End of Conference
For more information visit
http://www.bharatbook.com/detail.asp?id=133389&rt=Conference-on-Vaccine-Research-Innovation-2010.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Conference on Clinical Trials Asia Summit 2010
Clinical trials in India are finally becoming transparent. There has been a dramatic increase in the number of trials that have got officially registered in Clinical Trials Registry-India (CTRI). According to records collected by the Indian Council of Medical Research and the Drug Controller General's office, between July-December 2007, only 11 trials were registered. The number increased to 137 between Jan-Dec 2008 and then to an all-time high of 546 between Jan-Dec 2009. This year, while January saw 58 trials registered, February recorded 60. India has all the competitive advantages for conducting clinical trials. As the country is increasingly becoming a favoured destination for clinical trials, a gap analysis needs to be done to scale up all resources for clinical trials. This scale up is essential for India to cope with the large global clinical trial projects. It is no coincidence over the last decade or more of economic liberalization, and years of unprecedented growth, that India and parts of South Asia are becoming a preferred clinical research destination for multinational pharmaceutical and biotechnology corporations.
CTAS 2010 will examine the current issues faced in clinical trials operations, addressing the risks, timeline and budget stipulations, while effectively tackling key challenges in overcoming trials agreement and site contract arbitration problems. This summit will discuss the operational element of trial site management, strategic partnership with CROs and SMOs, patient, talent & investigators management in order to improve & optimise the overall drug development effectiveness and ROI. Discover on how to implement and benefit from electronic data management & monitoring cost effectively. This conference will be shared by leading industrial practitioners across the region to promote practical discussions; especially on the know-how to manage needs, variability of different countries and institutions to enhance clinical operational excellence and vigilance. Attendees will have the chance to learn, network and benchmark against the global top pharmas and local industry leaders on the best practices in talent, site, budget and performance management in clinical trials. The conference aims to provide a detailed analysis of what it takes to conduct clinical trials from a biopharmaceuticals and vaccines perspective in India and China and also addressing risk/benefit balance, anecdotal experiences of the multinational pharmaceutical industry in India and China, selection and role of CROs, logistics of operations, clinical trials management, government policies and pharmacovigilance.
CTAS 2010 will provide you with the data that you need to recognize this complex and rapidly-expanding sector. Knowing the future market, and what impact will that have on future business opportunities? This is your opportunity to stay ahead by learning the latest trends and networking with the trend setters. It gives us immense pleasure in welcoming you to the Clinical Trials Asia Summit '2010.
Key Speakers Include:
Akhilesh Sharma, Vice President & Global head Clinical management & Global Pharmacovigilance, Dr. Reddy’s,
Bakulesh Khamar, Executive Director – Research Cadila,
Deven Parmar Vice President - Clinical Research & Pharmacovigilance, Wockhardt,
Shashidhar Rao, India Operations Head (IID and IA&R), Novartis,
Mohan Bangalore, Senior Director & Site Head, Pfizer,
Parminder Kaur, Managing Director, RegPak BioPharma, Consulting, (Netherlands),
Ramesh Jagannathan, Director-Clinical Research, AstraZeneca,
Deepti Sanghavi, Medical Advisor- Clinical Research, Wockhardt Limited,
Arun Bhatt, President, Clininvent Research,
Milind Antani, Head-Pharma LifeSciences group, Nishith Desai, Associates,
Sanjay Zodpey, Director, Indian Institute of Public Health,
S.K.Bhattacharya, Medical Officer, Depart of Communicable Diseases, WHO (World Health Organisation),
Shailesh Mehta, Director Clinical R&D and Med Affairs, South Asia, Glaxosmithkline,
Roopa Basrur, Associate Director - Clinical Writing and Document, Quality, Pfizer,
Yamin ’Mo’ Khan, Executive Vice President, Clinical Development Pharma-Olam (U.K),
Marcus Hompesch, President – CEO, Clinical Research, (USA),
Larisa Nagra Singh, General Manager and Project Director, Voisin Consulting Life Science,
Darshan Bhatt, Consultant, Patient Safety and Pharmacovigilance,
Mala Srivastava, Partner, Nextvel Consulting,
R Ezhil Arasan, Managing Director, VRE Research Laboratories,
(Former Head of Medical Affairs & Differentiated Products, Development at Dr.Reddy's)
Key Themes Discussed at this conference:
*
Current trends of clinical trials environment.
*
How can you take advantage of the global market for clinical trials?
*
Discovering technologies and strategies for successful clinical trial management.
*
Analyzing the successes and challenges of Phase I and Phase II clinical trials.
*
Setting up clinical trial research hub & techniques for applying risk management principles.
*
Discover how to improve your supplier-client relationships.
*
Complete trials on schedule & budget by overcoming hurdles in investigator/patient recruitment.
*
Avoiding potential pitfalls of trials agreement.
*
Gather the latest regulatory updates impacting global and Indian clinical development.
*
Explore innovative strategies for outsourcing, what should you be looking for in a CRO?
*
Improving and optimizing site management and overall productivity of clinical operations.
*
Data management, CMC SCM, operational requirements & CRO infrastructure in India & South Asia.
*
Optimising clinical trials operation effectiveness and ROI through strategic site, patient, data and risk management in the regulated markets.
*
What are the issues with off-shoring trials to countries such as India & South Asia? – Solutions?
*
Working with limited budget to ensure on time study completion.
*
Motivating and managing clinical project teams to improve timeline and progress.
*
Exploring the efficacy and safety of new interventions in clinical trials.
*
Drawing and retaining clinical talent pool to minimise turnover in clinical studies.
*
Next generation of clinical trials – How big will the market be?
Who Should Attend:
*
Vice Presidents,
*
Directors Heads & Managers of: Clinical Research & Development,
*
Clinical Research Services,
*
Clinical Operations,
*
Clinical Data Management,
*
Clinical IT,
*
Clinical Trials,
*
Medical Affairs, Regulatory Affairs,
*
Compliance,
*
Quality Control/Assurance/GCP,
*
Clinical Study Design,
*
Safety Surveillance,
*
Subject Recruitment,
*
E-Clinical Systems.
Target Audience - Industry:
*
Pharmaceutical Organisations,
*
Generic pharmaceutical companies,
*
Contract Research Organisations ,
*
Patient Recruitment Companies,
*
Government- Department of Health,
*
Non-profit Organisations/Association,
*
Academics, Consultants.
Why should you attend:
Clinical Trials Asia Summit 2010 - "Improving clinical practice & trial success rates with improved technologies, strategies & alliance management"
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time meet the leading international vendors. showcasing the technology of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and technologies in the high-level conference.
DAY 1
19th August 2010,
08:30 – Coffee and registration.
09:30 – Chair's opening remarks.
09:40 – Examining the evolution of clinical trials.
*
Where does India stand in the current global clinical trials market?
*
How can you take advantage of the global market for clinical trials?
*
Identify the significance of the clinical trial in India and South Asia market
*
Emerging technologies that can be deployed to generate revenue.
*
Allied services - Data Management & IT services – Can they play significant role in outsourcing clinical trials?
10:20 Changing concept of conducting clinical trials.
*
Challenges in conduct of investigator initiated research.
*
Biomarkers and newer endpoints in oncology.
*
Structure of existing system for training and monitoring staff performance.
*
What are the common problems of staff monitoring and effective solutions to minimise cost for your trials.
*
Challenges in conducting medical device trials.
11:00 – Morning coffee & Discussion.
11:20 – “Factors limiting acceptability of foreign clinical data: EMEA perspective”
Parminder Kaur, Managing Director, RegPak BioPharma Consulting, (Netherlands).
12:00 – Panel Discussion: Evaluating key emerging markets for improved strategy.
*
Which emerging markets are hottest today?
*
Offshoring - Balancing the right opportunities and risks.
*
What makes each market unique and how do markets compare?
*
Successful budget development & analysis - How do sponsors develop study budgets? How do sites price their services?
*
How to go about tracking & collecting payments properly?
Moderator –
Shashidhar Rao, India Operations Head (IID and IA&R), Novartis.
Panelists –
*
Arun Bhatt, President, Clininvent Research,
*
Parminder Kaur, Managing Director, RegPak BioPharma Consulting, (Netherlands),
*
Deepti Sanghavi, Medical Advisor- Clinical Research, Wockhardt Limited,
*
Ramesh Jagannathan, Director-Clinical Research, AstraZeneca,
12:40 – Networking lunch.
14:00 – Impact of advanced technology in today's clinical trials.
*
Enable more reliable, smaller, faster, safer trials.
*
Benefits of Information Technology in clinical trials - (EDC), (CTMS), (CDMS), (DBMS).
*
Overcoming issues related with managing security, confidentiality and ethical concerns.
14:40 – Relationships: Sponsor – Site - CRO.
*
Three-way relationship between sponsors, sites and CROs realistic expectations, clear communications, shared understandings,
practical policies, and efficient problem resolution.
*
Identifying the anticipated advantages of a collaborative clinical trial alliance for greater efficiency and cost reduction.
*
Developing programs for successful partnership.
*
Quantitative analysis reveals rapid changes in the industry and trends for the future. How can sponsors, sites and CROs meet the challenges?
Arun Bhatt, President, Clininvent Research.
15:20 – Afternoon tea.
15:40 – Panel Discussion: Overcoming regulatory challenges in Asian clinical trials.
*
Introducing recent developments in regulatory affairs and legal challenges for clinical trials.
*
Understanding how Indian companies can work in harmony with the European legal framework.
*
Analysing the current scope and strategies of pharmaceutical / biopharmaceutical regulatory harmonization
*
Government incentives for Clinical Research in India.
*
Quality standards in clinical trials.
Moderator –
Milind Antani, Head-Pharma LifeSciences group, Nishith Desai Associates.
Panelists –
Sanjay Zodpey, Director, Indian Institute of Public Health,
16:20 – Safety data Management.
Darshan Bhatt, Consultant, Patient Safety and Pharmacovigilance,
17:00 - Start-up teams to manage clinical trials: Advantages and Limitations.
*
Structure and set-up of an effective start-up team.
*
Communication channels between start-up team, operations and Investigator sites.
*
Advantages and Limitations of managing projects under above structure.
Larisa Nagra Singh, General Manager and Project Director, Voisin Consulting Life Science,
17:30 - Logistics as a facilitator of growth in the pharma industry.
*
What are the current logistics challenges in pharma industry?
*
What are the recent applications of technology to aid the Clinical SCM?
*
Secure strategies – for maintaining your materials during transits.
*
Efficiency of a potential logistics – transforming the pharma sector.
18:00 - Chairperson's closing remarks and end of conference.
18:10 - Networking Drinks - Take your discussions further & build new relationships in a relaxed & informal setting...
DAY 2
20 th August 2010
08:30 – Coffee and registration.
09:30 – Chair's opening remarks.
R Ezhil Arasan, Managing Director, VRE Research Laboratories.
(Former Head of Medical Affairs & Differentiated Products Development at Dr.Reddy's)
09:40 – Opportunity trials of Clinical Research in India: Focusing on Phase I and Phase II
*
Reviewing the phase I and II clinical research environment in India.
*
Focus on related business models in conducting clinical trials in India.
*
Evaluating the opportunities of potential collaborations.
Deven Parmar Vice President - Clinical Research & Pharmacovigilance, Wockhardt,
10:20: Clinical Data Management (CDM) – Guidelines for a successful future.
Safety data management.
*
Good data review and validation practices.
*
Challenges! In medical coding.
*
Consideration in database designing & edit check programming.
*
Good programming practices and where can one go wrong in query management?
*
Developing protocols that generate useful data, practical for sites to implement, acceptable to subjects, and work internationally.
11:00 – Morning coffee & discussion.
11:20 – Innovative designing of clinical trials.
Akhilesh Sharma, Vice President & Global head Clinical management & Global Pharmacovigilance, Dr. Reddy's,
12:00 – Panel Discussion: Sourcing the right partners, Sponsor – Vendor partnerships.
*
How to work with your sponsor for a profitable study.
*
What do CRO look for in a good sponsor?
*
Analysing India's offering in large scale global trials: cost, resources, patient pool.
*
Avoiding mistakes in selecting an outsourcing partner to conduct clinical trials.
*
Quantitative analysis reveals rapid changes in the industry and trends for the future. How can sponsors, sites and CROs meet the challenges?
Moderator –
Shashidhar Rao, India Operations Head (IID and IA&R), Novartis.
Panelists –
Mohan Banglore, Senior Director & Site Head, Pfizer,
Marcus Hompesch, President – CEO, Profile Institute - Clinical Research, (USA),
Yamin 'Mo' Khan, Executive Vice President, Clinical Development, Pharm-Olam (UK),
Mala Srivastava, Partner, Nextvel Consulting,
12:40 – Networking lunch.
14:00 – Challenges of conducting Phase III cancer trails in India.
Bakulesh Khamar, Executive Director – Research, Cadila,
14:40 – Conducting large-scale community trials.
S.K.Bhattacharya, Medical Officer, Depart of Communicable Diseases, WHO (World Health Organisation).
15:20 – Afternoon tea.
15:40 – Exploring the efficacy and safety of new interventions in clinical trials.
Shailesh Mehta, Director Clinical R&D and Med Affairs, South Asia, Glaxosmithkline.
16:20 - Setting up a medical writing unit in India.
*
Outsourcing medical writing to India – a novel business model.
*
What factors are important at start-up and later on?
*
Measuring success in a subjective domain – metrics.
*
Challenges and solutions.
Roopa Basrur, Associate Director - Clinical Writing and Document Quality, Pfizer.
17:00 – Panel Discussion – SWOT analysis - Strength, Weakness, Opportunities & Threats of Clinical Trials in India (Overall review of this Clinical Trials Asia Summit 2010 conference).
*
Identifying market potential strengths and weakness.
*
Benefits of India - reducing costs, accelerating time to market?
*
Analysing India's offering in large scale global trials: cost, resources, patient pool.
*
Avoiding mistakes in selecting an outsourcing partner to conduct clinical trials.
Moderator:
Panellists:
Thuppil Venkatesh, Prof. St.John's Medical College & Principal Advisor, Quality Council of India,
17:30 Chairperson's closing remarks and end of conference.
Book Now:
1 Day Conference............Fee INR. 8824.00
2 Day Conference............Fee INR. 11030.00
For more information visit
http://www.bharatbook.com/detail.asp?id=104776&rt=Conference-on-Clinical-Trials-Asia-Summit-2010.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
CTAS 2010 will examine the current issues faced in clinical trials operations, addressing the risks, timeline and budget stipulations, while effectively tackling key challenges in overcoming trials agreement and site contract arbitration problems. This summit will discuss the operational element of trial site management, strategic partnership with CROs and SMOs, patient, talent & investigators management in order to improve & optimise the overall drug development effectiveness and ROI. Discover on how to implement and benefit from electronic data management & monitoring cost effectively. This conference will be shared by leading industrial practitioners across the region to promote practical discussions; especially on the know-how to manage needs, variability of different countries and institutions to enhance clinical operational excellence and vigilance. Attendees will have the chance to learn, network and benchmark against the global top pharmas and local industry leaders on the best practices in talent, site, budget and performance management in clinical trials. The conference aims to provide a detailed analysis of what it takes to conduct clinical trials from a biopharmaceuticals and vaccines perspective in India and China and also addressing risk/benefit balance, anecdotal experiences of the multinational pharmaceutical industry in India and China, selection and role of CROs, logistics of operations, clinical trials management, government policies and pharmacovigilance.
CTAS 2010 will provide you with the data that you need to recognize this complex and rapidly-expanding sector. Knowing the future market, and what impact will that have on future business opportunities? This is your opportunity to stay ahead by learning the latest trends and networking with the trend setters. It gives us immense pleasure in welcoming you to the Clinical Trials Asia Summit '2010.
Key Speakers Include:
Akhilesh Sharma, Vice President & Global head Clinical management & Global Pharmacovigilance, Dr. Reddy’s,
Bakulesh Khamar, Executive Director – Research Cadila,
Deven Parmar Vice President - Clinical Research & Pharmacovigilance, Wockhardt,
Shashidhar Rao, India Operations Head (IID and IA&R), Novartis,
Mohan Bangalore, Senior Director & Site Head, Pfizer,
Parminder Kaur, Managing Director, RegPak BioPharma, Consulting, (Netherlands),
Ramesh Jagannathan, Director-Clinical Research, AstraZeneca,
Deepti Sanghavi, Medical Advisor- Clinical Research, Wockhardt Limited,
Arun Bhatt, President, Clininvent Research,
Milind Antani, Head-Pharma LifeSciences group, Nishith Desai, Associates,
Sanjay Zodpey, Director, Indian Institute of Public Health,
S.K.Bhattacharya, Medical Officer, Depart of Communicable Diseases, WHO (World Health Organisation),
Shailesh Mehta, Director Clinical R&D and Med Affairs, South Asia, Glaxosmithkline,
Roopa Basrur, Associate Director - Clinical Writing and Document, Quality, Pfizer,
Yamin ’Mo’ Khan, Executive Vice President, Clinical Development Pharma-Olam (U.K),
Marcus Hompesch, President – CEO, Clinical Research, (USA),
Larisa Nagra Singh, General Manager and Project Director, Voisin Consulting Life Science,
Darshan Bhatt, Consultant, Patient Safety and Pharmacovigilance,
Mala Srivastava, Partner, Nextvel Consulting,
R Ezhil Arasan, Managing Director, VRE Research Laboratories,
(Former Head of Medical Affairs & Differentiated Products, Development at Dr.Reddy's)
Key Themes Discussed at this conference:
*
Current trends of clinical trials environment.
*
How can you take advantage of the global market for clinical trials?
*
Discovering technologies and strategies for successful clinical trial management.
*
Analyzing the successes and challenges of Phase I and Phase II clinical trials.
*
Setting up clinical trial research hub & techniques for applying risk management principles.
*
Discover how to improve your supplier-client relationships.
*
Complete trials on schedule & budget by overcoming hurdles in investigator/patient recruitment.
*
Avoiding potential pitfalls of trials agreement.
*
Gather the latest regulatory updates impacting global and Indian clinical development.
*
Explore innovative strategies for outsourcing, what should you be looking for in a CRO?
*
Improving and optimizing site management and overall productivity of clinical operations.
*
Data management, CMC SCM, operational requirements & CRO infrastructure in India & South Asia.
*
Optimising clinical trials operation effectiveness and ROI through strategic site, patient, data and risk management in the regulated markets.
*
What are the issues with off-shoring trials to countries such as India & South Asia? – Solutions?
*
Working with limited budget to ensure on time study completion.
*
Motivating and managing clinical project teams to improve timeline and progress.
*
Exploring the efficacy and safety of new interventions in clinical trials.
*
Drawing and retaining clinical talent pool to minimise turnover in clinical studies.
*
Next generation of clinical trials – How big will the market be?
Who Should Attend:
*
Vice Presidents,
*
Directors Heads & Managers of: Clinical Research & Development,
*
Clinical Research Services,
*
Clinical Operations,
*
Clinical Data Management,
*
Clinical IT,
*
Clinical Trials,
*
Medical Affairs, Regulatory Affairs,
*
Compliance,
*
Quality Control/Assurance/GCP,
*
Clinical Study Design,
*
Safety Surveillance,
*
Subject Recruitment,
*
E-Clinical Systems.
Target Audience - Industry:
*
Pharmaceutical Organisations,
*
Generic pharmaceutical companies,
*
Contract Research Organisations ,
*
Patient Recruitment Companies,
*
Government- Department of Health,
*
Non-profit Organisations/Association,
*
Academics, Consultants.
Why should you attend:
Clinical Trials Asia Summit 2010 - "Improving clinical practice & trial success rates with improved technologies, strategies & alliance management"
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time meet the leading international vendors. showcasing the technology of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and technologies in the high-level conference.
DAY 1
19th August 2010,
08:30 – Coffee and registration.
09:30 – Chair's opening remarks.
09:40 – Examining the evolution of clinical trials.
*
Where does India stand in the current global clinical trials market?
*
How can you take advantage of the global market for clinical trials?
*
Identify the significance of the clinical trial in India and South Asia market
*
Emerging technologies that can be deployed to generate revenue.
*
Allied services - Data Management & IT services – Can they play significant role in outsourcing clinical trials?
10:20 Changing concept of conducting clinical trials.
*
Challenges in conduct of investigator initiated research.
*
Biomarkers and newer endpoints in oncology.
*
Structure of existing system for training and monitoring staff performance.
*
What are the common problems of staff monitoring and effective solutions to minimise cost for your trials.
*
Challenges in conducting medical device trials.
11:00 – Morning coffee & Discussion.
11:20 – “Factors limiting acceptability of foreign clinical data: EMEA perspective”
Parminder Kaur, Managing Director, RegPak BioPharma Consulting, (Netherlands).
12:00 – Panel Discussion: Evaluating key emerging markets for improved strategy.
*
Which emerging markets are hottest today?
*
Offshoring - Balancing the right opportunities and risks.
*
What makes each market unique and how do markets compare?
*
Successful budget development & analysis - How do sponsors develop study budgets? How do sites price their services?
*
How to go about tracking & collecting payments properly?
Moderator –
Shashidhar Rao, India Operations Head (IID and IA&R), Novartis.
Panelists –
*
Arun Bhatt, President, Clininvent Research,
*
Parminder Kaur, Managing Director, RegPak BioPharma Consulting, (Netherlands),
*
Deepti Sanghavi, Medical Advisor- Clinical Research, Wockhardt Limited,
*
Ramesh Jagannathan, Director-Clinical Research, AstraZeneca,
12:40 – Networking lunch.
14:00 – Impact of advanced technology in today's clinical trials.
*
Enable more reliable, smaller, faster, safer trials.
*
Benefits of Information Technology in clinical trials - (EDC), (CTMS), (CDMS), (DBMS).
*
Overcoming issues related with managing security, confidentiality and ethical concerns.
14:40 – Relationships: Sponsor – Site - CRO.
*
Three-way relationship between sponsors, sites and CROs realistic expectations, clear communications, shared understandings,
practical policies, and efficient problem resolution.
*
Identifying the anticipated advantages of a collaborative clinical trial alliance for greater efficiency and cost reduction.
*
Developing programs for successful partnership.
*
Quantitative analysis reveals rapid changes in the industry and trends for the future. How can sponsors, sites and CROs meet the challenges?
Arun Bhatt, President, Clininvent Research.
15:20 – Afternoon tea.
15:40 – Panel Discussion: Overcoming regulatory challenges in Asian clinical trials.
*
Introducing recent developments in regulatory affairs and legal challenges for clinical trials.
*
Understanding how Indian companies can work in harmony with the European legal framework.
*
Analysing the current scope and strategies of pharmaceutical / biopharmaceutical regulatory harmonization
*
Government incentives for Clinical Research in India.
*
Quality standards in clinical trials.
Moderator –
Milind Antani, Head-Pharma LifeSciences group, Nishith Desai Associates.
Panelists –
Sanjay Zodpey, Director, Indian Institute of Public Health,
16:20 – Safety data Management.
Darshan Bhatt, Consultant, Patient Safety and Pharmacovigilance,
17:00 - Start-up teams to manage clinical trials: Advantages and Limitations.
*
Structure and set-up of an effective start-up team.
*
Communication channels between start-up team, operations and Investigator sites.
*
Advantages and Limitations of managing projects under above structure.
Larisa Nagra Singh, General Manager and Project Director, Voisin Consulting Life Science,
17:30 - Logistics as a facilitator of growth in the pharma industry.
*
What are the current logistics challenges in pharma industry?
*
What are the recent applications of technology to aid the Clinical SCM?
*
Secure strategies – for maintaining your materials during transits.
*
Efficiency of a potential logistics – transforming the pharma sector.
18:00 - Chairperson's closing remarks and end of conference.
18:10 - Networking Drinks - Take your discussions further & build new relationships in a relaxed & informal setting...
DAY 2
20 th August 2010
08:30 – Coffee and registration.
09:30 – Chair's opening remarks.
R Ezhil Arasan, Managing Director, VRE Research Laboratories.
(Former Head of Medical Affairs & Differentiated Products Development at Dr.Reddy's)
09:40 – Opportunity trials of Clinical Research in India: Focusing on Phase I and Phase II
*
Reviewing the phase I and II clinical research environment in India.
*
Focus on related business models in conducting clinical trials in India.
*
Evaluating the opportunities of potential collaborations.
Deven Parmar Vice President - Clinical Research & Pharmacovigilance, Wockhardt,
10:20: Clinical Data Management (CDM) – Guidelines for a successful future.
Safety data management.
*
Good data review and validation practices.
*
Challenges! In medical coding.
*
Consideration in database designing & edit check programming.
*
Good programming practices and where can one go wrong in query management?
*
Developing protocols that generate useful data, practical for sites to implement, acceptable to subjects, and work internationally.
11:00 – Morning coffee & discussion.
11:20 – Innovative designing of clinical trials.
Akhilesh Sharma, Vice President & Global head Clinical management & Global Pharmacovigilance, Dr. Reddy's,
12:00 – Panel Discussion: Sourcing the right partners, Sponsor – Vendor partnerships.
*
How to work with your sponsor for a profitable study.
*
What do CRO look for in a good sponsor?
*
Analysing India's offering in large scale global trials: cost, resources, patient pool.
*
Avoiding mistakes in selecting an outsourcing partner to conduct clinical trials.
*
Quantitative analysis reveals rapid changes in the industry and trends for the future. How can sponsors, sites and CROs meet the challenges?
Moderator –
Shashidhar Rao, India Operations Head (IID and IA&R), Novartis.
Panelists –
Mohan Banglore, Senior Director & Site Head, Pfizer,
Marcus Hompesch, President – CEO, Profile Institute - Clinical Research, (USA),
Yamin 'Mo' Khan, Executive Vice President, Clinical Development, Pharm-Olam (UK),
Mala Srivastava, Partner, Nextvel Consulting,
12:40 – Networking lunch.
14:00 – Challenges of conducting Phase III cancer trails in India.
Bakulesh Khamar, Executive Director – Research, Cadila,
14:40 – Conducting large-scale community trials.
S.K.Bhattacharya, Medical Officer, Depart of Communicable Diseases, WHO (World Health Organisation).
15:20 – Afternoon tea.
15:40 – Exploring the efficacy and safety of new interventions in clinical trials.
Shailesh Mehta, Director Clinical R&D and Med Affairs, South Asia, Glaxosmithkline.
16:20 - Setting up a medical writing unit in India.
*
Outsourcing medical writing to India – a novel business model.
*
What factors are important at start-up and later on?
*
Measuring success in a subjective domain – metrics.
*
Challenges and solutions.
Roopa Basrur, Associate Director - Clinical Writing and Document Quality, Pfizer.
17:00 – Panel Discussion – SWOT analysis - Strength, Weakness, Opportunities & Threats of Clinical Trials in India (Overall review of this Clinical Trials Asia Summit 2010 conference).
*
Identifying market potential strengths and weakness.
*
Benefits of India - reducing costs, accelerating time to market?
*
Analysing India's offering in large scale global trials: cost, resources, patient pool.
*
Avoiding mistakes in selecting an outsourcing partner to conduct clinical trials.
Moderator:
Panellists:
Thuppil Venkatesh, Prof. St.John's Medical College & Principal Advisor, Quality Council of India,
17:30 Chairperson's closing remarks and end of conference.
Book Now:
1 Day Conference............Fee INR. 8824.00
2 Day Conference............Fee INR. 11030.00
For more information visit
http://www.bharatbook.com/detail.asp?id=104776&rt=Conference-on-Clinical-Trials-Asia-Summit-2010.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Saturday, July 24, 2010
Global Top 10 Pharmaceutical Companies - Industry, Financial and SWOT Analysis
This report analyzes the global pharmaceutical market in terms of market size, key drivers and resistors, trends and competitive positioning. It includes profiles of the top ten companies in the industry along with 5-year financial analysis and in-depth SWOT analysis.
Scope
* Performance of the global pharmaceutical market on the basis of sales, volume and respective growth patterns over the past five years
* Obtain descriptive profiles of the top ten leading players including strategic initiatives undertaken in the last 12 months
* Analysis of the Strengths, Weaknesses, Opportunities and Threats of the top 10 pharmaceutical companies along with business overview and financials
* Benchmark the performance of the top 10 players for the past five years; includes revenue comparison, profitability analysis, industry-specific ratios
Highlights
The global pharmaceutical market generated total revenues of $615.1 billion in 2008, representing a compound annual growth rate (CAGR) of 4.7% for the period spanning 2004-2008.
The cardiovascular segment was the market''s most lucrative in 2008, generating total revenues of $121.7 billion, equivalent to 19.8% of the market''s overall value.
The performance of the market is forecast to decelerate, with an anticipated CAGR of 3.6% for the five-year period 2008-2013, which is expected to drive the market to a value of $734 billion by the end of 2013.
Reasons to Purchase
* Save time, money and resources on analyzing the top 10 pharmaceutical companies using this report
* Analyze the global pharmaceutical market with key industry metrics including market value, market volume, and growth forecasts
* Assess the intensity of competition based on the 5-forces model including degree of rivalry, substitutes, new entrants, buyer power and supplier power
For more information visit
http://www.bharatbook.com/detail.asp?id=141531&rt=Global-Top-10-Pharmaceutical-Companies-Industry-Financial-and-SWOT-Analysis.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Scope
* Performance of the global pharmaceutical market on the basis of sales, volume and respective growth patterns over the past five years
* Obtain descriptive profiles of the top ten leading players including strategic initiatives undertaken in the last 12 months
* Analysis of the Strengths, Weaknesses, Opportunities and Threats of the top 10 pharmaceutical companies along with business overview and financials
* Benchmark the performance of the top 10 players for the past five years; includes revenue comparison, profitability analysis, industry-specific ratios
Highlights
The global pharmaceutical market generated total revenues of $615.1 billion in 2008, representing a compound annual growth rate (CAGR) of 4.7% for the period spanning 2004-2008.
The cardiovascular segment was the market''s most lucrative in 2008, generating total revenues of $121.7 billion, equivalent to 19.8% of the market''s overall value.
The performance of the market is forecast to decelerate, with an anticipated CAGR of 3.6% for the five-year period 2008-2013, which is expected to drive the market to a value of $734 billion by the end of 2013.
Reasons to Purchase
* Save time, money and resources on analyzing the top 10 pharmaceutical companies using this report
* Analyze the global pharmaceutical market with key industry metrics including market value, market volume, and growth forecasts
* Assess the intensity of competition based on the 5-forces model including degree of rivalry, substitutes, new entrants, buyer power and supplier power
For more information visit
http://www.bharatbook.com/detail.asp?id=141531&rt=Global-Top-10-Pharmaceutical-Companies-Industry-Financial-and-SWOT-Analysis.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Subscribe to:
Posts (Atom)